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Abstract 
Iron is an essential nutrient for normal cellular functioning, but excess iron retention is a 
hallmark of breast cancer, used to fuel cancer cells proliferative demands.  Breast cancer cells 
alter genes that control iron metabolism to promote accumulation of cellular iron. One way 
breast cancer cells retain iron is through decreased iron export.  Breast cancer cells have 
reduced expression of the iron efflux pump, ferroportin (FPN). FPN is reduced by the iron 
regulating peptide hepcidin, which binds to FPN and triggers its degradation, resulting in 
decreased iron export. Hepcidin is elevated in breast cancer to promote accumulation of cellular 
iron. However, the pathways responsible for elevated hepcidin in breast cancer cells have never 
been investigated.  
In this thesis we utilize several culture methods to examine the full spectrum of hepcidin 
regulation in breast cancer including two- and three-dimensional culture of established cell lines 
and primary breast cells, as well as co-culture systems with stromal cells. Ultimately, we reveal 
a complex hepcidin regulatory network involving protein molecules and spatial cues, consisting 
of changes at the cellular, dimensional and microenvironmental levels.  Specifically, we found 
regulation of hepcidin by ligands including bone morphogenetic proteins (BMPs), interleukin-6 
(IL-6) and growth-differentiation factor-15 (GDF-15) in an autocrine and paracrine fashion, as 
well as novel regulation by the microenvironment, specifically by contribution of tumor 
associated fibroblasts and extracellular matrix proteins.  Additionally, we reveal global changes 
in iron metabolism in breast cancer spheroids and that targeting enhanced iron levels present in 
spheroids results in disaggregation and spheroid cell death.  Thus, targeting iron in breast 
tumors may be an attractive molecular strategy for selective killing of breast cancer cells.
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Introduction and Background 
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A.) Breast Cancer 
 
 Aside from skin cancer, breast cancer is the leading cancer type among American 
women, with an astounding 1 in 8 females having the chance of invasive breast cancer 
diagnosis in their lifetime [1]. This year, 252,710 new cases of invasive breast cancer are 
expected among U.S. women, along with 63,410 new cases of non-invasive ducal carcinoma in 
situ (DCIS) [1]. Although detection methods and treatments have improved tremendously 
throughout the past few decades, 40,610 U.S. women are expected to succumb to the disease 
in 2017 [1].  Besides lung cancer, the predicted number of deaths for breast cancer is higher 
than those for any other cancer type in women [1].    
 Depending on the tumor size, molecular sub-type, stage and lymph node involvement, 
treatment options include surgery (lumpectomy or mastectomy), hormonal therapy, radiation 
and/or chemotherapy. Although treatments have improved and the 5 year survival rate has 
reached 91%, the high incidence of breast cancer indicates that more prevention and early 
detection methods are desired [1].  Interestingly, although it has been praised for its ability to 
capture breast tumors at their earliest stages, mammography has become a controversial 
detection method throughout recent years [2].  Improvements in the technology and detection 
limits have dramatically increased the number of “abnormal” mammograms, leading to 
sometimes unnecessary and sometimes life-saving biopsies and treatments [3]. The challenge 
is to determine what abnormalities may progress to invasive carcinomas and what abnormalities 
will never progress to invasive disease. Therefore, it is imperative to understand the molecular 
changes that occur during early tumor progression. The propagation of primary patient samples 
in vitro, both normal and tumor from the same patient, allow us to follow the molecular changes 
that occur and contribute to tumor progression [4].  We will utilize these samples in this thesis 
among other in vitro culture systems to investigate molecular changes that occur during 
tumorigenesis, specifically with regards to iron metabolism.  
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 In addition to better detection and prevention, for those 40% of women whose cancer 
was detected after it has spread beyond the breast, 5-year survival rates dip to 85% for disease 
progression to regional lymph nodes and 26% for progression to distal sites [1]. This drop-off in 
survival indicates that current traditional treatment strategies are ineffective at treating disease 
that has spread. Alternative therapies, such as iron chelation and induction of iron dependent 
cell death, termed ferroptosis, are emerging as innovative ways to halt tumor progression and 
disease spread, when traditional treatment strategies fail [5, 6].   
 
B.) Iron metabolism 
I. Systemic and Cellular Iron Homeostasis  
 Iron is an essential nutrient and plays a vital role in maintaining proper function at both a 
systemic and cellular level. Iron is a co-factor in many heme and iron containing enzymes 
necessary for processes such as DNA synthesis, cell cycle, iron-sulfur cluster biogenesis and 
energy generation [6].  However, iron must be tightly regulated, as the element has the ability to 
cycle between reduced and oxidized forms, giving iron the potential to partake in free radical 
generating reactions and damage cellular DNA.  As there is no known mechanism for iron 
excretion from the body, iron homeostasis is maintained by careful control of iron intake and 
recycling. 
 Dietary iron (mainly in the form of ferric (Fe3+) iron) is absorbed in the intestinal 
enterocytes through cooperative action of a ferric reductase, such as duodenal cytochrome B 
(DCYTB), and divalent metal transporter 1 (DMT1).  Reduced (ferrous (Fe2+)) iron is then 
transported to the basal surface of the duodenal enterocyte, where iron is re-oxidized by 
hephaestin (HEPH) and exported through the only known mammalian iron exporter, ferroportin 
(FPN). Ferric iron is loaded onto the carrier protein, transferrin (TF), where it circulates 
throughout the body destined for areas that require iron, such as peripheral tissues. On 
peripheral cells, transferrin bound iron is recognized by transferrin receptor (TFR1) where the 
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binding of the holo-TF to TFR1 triggers endocytosis of the holo-TF-TFR1 complex.  In the acidic 
environment of the endosome, iron is released from TF and is reduced back to its metabolically 
active state by the ferric reductase, STEAP3.  Ferrous iron is transported out of the endosome 
into the cytosol by DMT1, where it is now part of the metabolically active labile iron pool (LIP). 
This metabolically active iron is utilized by the cell for processes mentioned above.  As 
metabolically labile iron that is not utilized by the cell can participate in free radical generating 
reactions, any excess iron is either carefully stored in the iron storage protein Ferritin (FT) or 
effluxed out of the cell by FPN, where it is loaded back onto TF for further circulation.  When 
systemic iron levels are high, hepcidin is produced by the liver, whose function is to bind to FPN 
and trigger its degradation, leading to decreased iron efflux from enterocytes into circulation.  
Hepcidin is also produced locally by peripheral cells, where it also functions to degrade FPN on 
neighboring cells for decreased iron export and accumulation of intracellular iron [7-9]. An 
overview of the main players involved in iron absorption and metabolism are shown in Figure 1-
1 and detailed in [6, 10].    
 In addition to hepcidin, intracellular iron levels can be regulated by the iron regulatory 
proteins 1 and 2 (IRP1 and IRP2) [6]. These proteins control intracellular iron by binding to iron 
responsive elements (IREs) on promoters of iron related genes such as FT, FPN and TFR1 
when iron is low.  The IRE can be found at either the 3’ untranslated region (UTR) for genes 
such as TFR1, where binding of IRPs stabilizes mRNA or at the 5’ UTR for FT and FPN, where 
binding of IRP inhibits mRNA translation. Under high iron conditions, IRP2 is degraded and 
IRP1 gains enzymatic activity as a cytosolic aconitase, rendering neither able to bind to IREs, 
reducing TFR1 and increasing FT and FPN for overall reduction of cellular iron.  
 
II. Iron and cancer  
 
 The relationship between iron and cancer has been widely observed for many years [6, 
11].  Large population based studies have all supported a model in which elevated body iron 
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levels are associated with increased cancer risk. Although each approach has study limitations, 
four main approaches have been utilized to perceive such a concrete observation.  First, studies 
examined markers of iron stores, such as TF saturation, and found that TF saturation was 
elevated in men who developed cancer than those men who did not [11, 12]. A second 
approach examined the association between dietary iron and cancer risk.  Numerous studies 
found higher dietary iron intake to be associated with increased risk of cancer, although the 
strength of the association varied by study [13-15]. A third epidemiological link between iron and 
cancer risk utilized a genetic approach, where patients with genetic disorders of iron overload, 
such as hereditary hemochromatosis, were found to have a 20-200 fold increased incidence of 
developing hepatocellular carcinoma, and may be at risk for additional cancers such as breast, 
colorectal and others [16-19]. A final approach examined the effect of reducing body iron stores 
and cancer risk.  Studies found that frequent phlebotomy over about 5 years in elderly men with 
peripheral artery diseases reduced overall cancer risk as well as cancer-specific death [20].  On 
the other hand, it is believed that increased breast cancer risk in post-menopausal women is in 
part due to increased body iron levels as a result of decreased blood loss after menstruation 
cessation [21]. Taken together, compilation of numerous studies utilizing all four approaches 
has painted a clear connection between increased body iron and overall cancer risk.   
 In addition to clinical based studies, which only examine an association between iron 
and cancer risk, iron retention at the cellular level in cancer cells has also been observed.  This 
has prompted extensive research assessing mis-regulation of iron homeostasis to elucidate a 
direct role of iron in cancer progression.  Iron not only functions to facilitate cell proliferation, but 
excess iron has the ability to generate free radicals that can result in genome instability and 
promote transformation [22, 23].  In attempts to determine the connection between excess iron 
and cancer, investigation into the control of iron metabolism at the molecular level is emerging.  
It has recently been demonstrated that many iron metabolism proteins, originally studied for 
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their role in systemic iron homeostasis, are utilized for cellular iron metabolism in peripheral 
tissues, such as the breast [7, 24].   
 Many alterations of the proteins that control cellular iron metabolism have been 
implicated in cancer, including breast cancer, and these cancer-specific protein modifications 
result in increased intracellular iron, assumed to meet the growth and proliferative demands of 
cancer cells [6, 25].  Specifically, proteins that control cellular iron uptake and efflux are altered 
to promote accumulation of intracellular iron. TFR1 is highly expressed in many tumor types, 
including breast cancer, to promote increased iron import [26] and antibodies against TFR1 
have been shown to inhibit tumor growth [27]. Additionally, iron export is deceased in cancer 
cells, through modulation of the FPN-hepcidin regulatory axis (Figure 1-2) [6].  FPN is reduced 
on the surface of breast, prostate, ovarian and hepatocellular cancer cells [7, 8, 28, 29].  
Interestingly, reduced FPN in breast tumors was associated with reduced metastasis-free 
survival, suggesting that FPN is predictive of patient outcome [7].   FPN is regulated at the 
transcriptional, post-transcriptional and post-translational levels. For the basis of this thesis, we 
will focus on post-translational regulation of FPN by hepcidin, the negative regulator of FPN 
protein expression, as described above.  Hepcidin is also altered in cancer, with elevated 
expression associated with increased cancer risk.  Not only is liver produced systemic hepcidin 
elevated in multiple cancer types [30-35], but hepcidin is also produced by peripheral cells and 
elevated in cancer cells compared to normal cells for local targeting of FPN for degradation 
within tumors [7-9, 28].  As this thesis focuses on hepcidin and the pathways that control its 
expression in breast cancer, a detailed introduction to hepcidin and its regulation is provided 
next.  
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C.) Hepcidin 
I. Discovery and role 
 Hepcidin was first discovered by independent groups in 2000 and 2001 as a small 
peptide with potent antibacterial activity [36, 37]. Expressed predominantly in the liver, hepcidin 
is encoded by the HAMP gene where it is synthesized as an 84 amino acid pre-pro-peptide with 
an N-terminal endoplasmic reticulum target sequence and a C-terminal consensus furin site for 
cleavage [37]. Cleavage at both sites renders the peptide active where it is rapidly secreted into 
circulation as a 25 amino acid bioactive hormone [38].  
 Shortly after its discovery, hepcidin was found to play a central role in systemic iron 
homeostasis, as well as iron storage in macrophages, and is now commonly referred to the 
master regulator of iron metabolism [39, 40].  It was determined that hepcidin regulates 
systemic iron by binding to FPN on intestinal enterocytes and macrophages for control of dietary 
iron and iron recycling respectively, leading to the internalization and degradation of hepcidin 
bound FPN in the lysosome [41-43]. Hepcidin levels can be controlled depending on the 
systemic need for iron.  For example, when body iron levels are high, hepcidin is induced and 
secreted by the liver, where it travels through the circulation for targeting of FPN for 
degradation, leading to reduced iron uptake from the diet and reduced iron from macrophage 
stores. When body iron levels are low, hepcidin is reduced, allowing for increased uptake of 
dietary iron and release of iron from macrophages. Careful control of hepcidin leads to 
homeostasis of systemic iron levels.  
 In addition to the role of the hepcidin-FPN axis in control of systemic iron homeostasis, 
this axis seems to be conserved for control of cellular iron homeostasis in tissues such as the 
breast, prostate and brain [7-9]. Hepcidin is produced from cells within these peripheral tissues 
for local control of FPN and intracellular iron levels. As mentioned above, hepcidin has been 
found to be elevated in serum of breast cancer patients as well as increased in cancer cells of 
peripheral tissues, suggesting an association between hepcidin and cancer at both the systemic 
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and local level [7, 8, 28, 30-35, 44]. It is expected that increased hepcidin leads to accumulation 
of intracellular iron within tumors, resulting in tumor cell growth and progression. Interestingly, 
the combined expression of ferroportin and hepcidin has been shown to be a powerful predictor 
of survival in breast cancer patient cohorts [7].  Furthermore, knockdown of hepcidin in breast 
tumor cells inhibits growth of breast tumor xenografts, indicating that hepcidin produced by 
tumor cells is an important contributor to tumor growth [28].  Thus, the FPN-hepcidin regulatory 
axis has significant impact on tumor growth and disease progression in breast cancer patients.   
II. Regulation 
 Due to the key role of hepatic hepcidin in maintenance of systemic iron homeostasis, 
mechanisms that regulate hepcidin synthesis have been intensively studied in hepatocytes 
since its discovery. Depending on the requirement for hepatic hepcidin and iron levels, 
mechanisms have been identified that both positively and negatively regulate the peptide 
hormone. 
a.) Positive Regulation 
In order to reduce efflux of iron from intestinal enterocytes and macrophages, hepcidin 
production must be elevated to reduce iron levels in circulation. In order to achieve this, 
hepcidin is positively regulated by iron itself through a pathway involving the bone 
morphogenetic protein (BMP) pathway and downstream signaling components, the Sma and 
mothers against decapentaplegic vertebrate homologs (SMADs) [45].  The BMPs are a 
subfamily of the transforming growth factor beta (TGF-β) superfamily, which controls a wide 
array of growth factor functions, such as bone formation [46]. The connection between the BMP 
pathway and iron homeostasis was first observed when hepatocyte-specific SMAD4 knock out 
mice were found to have severe iron overload phenotype [47]. It was discovered that there was 
a 100-fold reduction in hepatic hepcidin mRNA in the livers of these mice, indicating the role of 
SMAD4 as an essential transcriptional regulator of hepcidin.  Since then, many studies have 
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found that several BMPs and other ligands of the TGFβ family are capable of inducing hepcidin 
expression in hepatocytes and other cell types [8, 48].  However, researchers have pinpointed 
BMP6 as the main ligand for positive regulation of hepcidin transcription by iron in vivo [49, 50]. 
The precise mechanism by which iron induces BMPs as well as the cell type source of BMPs for 
positive regulation for hepcidin remains unknown.  
More recently, other members of the BMP signaling pathway have been shown to 
regulate hepcidin.  These were identified through mutational analysis of hereditary 
hemochromatosis patients. Specifically, patients with mutations in hemojuvelin (HJV), a BMP 
co-receptor, were found to have inappropriately low levels of hepcidin, indicating an important 
role of HJV in hepcidin regulation [51, 52]. Additionally, mutations in additional membrane iron 
sensors, transferrin receptor 2 (TFR2) or hemochromatosis protein (HFE), result in a subtle 
decrease in hepcidin production, leading to a less severe form of HH [53, 54].  It is believed that 
increasing concentrations of TF-bound iron leads to dissociation of HFE from TFR1 (the main 
iron import protein) at the cell membrane, allowing it to associate with TFR2 [55].  This allows 
for stabilization of TFR2 to activate the downstream BMP pathway, although the direct 
connection between TFR2 and BMP-SMAD pathway activation are unknown.  
In addition to hepcidin regulation by iron, hepcidin is also greatly regulated by 
inflammation, as hepcidin was first described as a peptide with antimicrobial properties [37].  It 
is believed that regulation of hepcidin by inflammation evolved as a host protective mechanism 
against microbes by reducing body iron levels that microbes require to flourish [56].  A direct 
connection between iron and inflammation was first demonstrated when treatment of 
hepatocytes with lipopolysaccharide (LPS) stimulated hepcidin transcription [39]. Further 
analysis revealed that type II acute phase cytokines, not type I cytokines, induce hepcidin [57]. 
Specifically, the main and most robust cytokine for hepcidin transcription in vivo was found to be 
IL-6 [57]. IL-6 activates Janus kinase 2 (JAK2) and the corresponding downstream signal 
transducers and activators of transcription 3 (STAT3) [58].  Upon activation through 
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phosphorylation, STAT3 translocates to the nucleus and binds to the STAT3 element on the 
hepcidin promoter for transcriptional induction of hepcidin [58]. It is interesting to note that 
cross-talk between the BMPs and IL-6 has been observed, for even greater control over 
hepcidin induction [59].  
b.) Negative Regulation 
Since hepcidin is the main regulator of systemic iron homeostasis, mechanisms must be 
in place to suppress its expression when increased body iron levels are needed. One such 
example is during erythropoiesis.  Due to increased demand during red blood cell formation, 
hepcidin must be suppressed. Although originally thought to be direct negative regulation by 
erythropoietin (EPO), further studies have suggested erythroferrone or growth differentiation 
factor 15 (GDF-15) to be the erythroid factor that negatively regulates hepcidin, although some 
of these studies were conducted in diseased states, such as β-thalassemia [60-63].  A full 
understanding of erythroid mediated negative regulation of hepcidin remains incomplete.  
In parallel to erythropoietic control of hepcidin suppression, hypoxia has been shown to 
reduce hepcidin levels.  Low oxygen conditions stimulate red blood cell production, resulting in 
increased demand for iron and thus hepcidin suppression [64].  The first molecular connection 
between hepcidin and oxygen levels was a study in which a hypoxia inducible factor 1 (HIF1α) 
hepatocyte-specific deletion showed no decrease in hepcidin during hypoxia or iron deficiency, 
suggesting hypoxic regulation of hepcidin is mediated by HIF1α [65]. The study went on to 
confirm that HIF1α binds to the hypoxia responsive element on the hepcidin promoter to inhibit 
gene transcription [65]. However, other studies have suggested negative regulation of hepcidin 
via hypoxia to involve HIF2α or and indirect mechanism through hypoxia, such as hypoxia 
leading to increased cleavage of HJV, which sequesters BMPs and inhibits their activation of 
the downstream signaling pathway [66-68]. Similar to erythropoietic regulation, negative 
regulation of hepcidin by hypoxia is incompletely understood.  
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Lastly, another molecular strategy for hepcidin suppression is through inhibition of 
positive regulators of hepcidin.  For example, mutations in the TMPRSS6 gene, which encodes 
a type II transmembrane serine protease called matriptase-2, results in increased hepcidin 
levels and severe anemia that does not respond to traditional therapy [69]. It was determined 
that matriptase-2 cleaves the BMP co-receptor HJV leading to reduced BMP signaling for 
reduction of hepcidin [70].  Similarly, Scelerostin domain containing 1 protein (SOSTDC1) 
sequesters BMP ligands resulting in diminished BMP signaling and has been found to be a 
negative regulator of hepcidin in prostate cancer cells [8, 71]. 
c.) Additional Regulators  
 
 More recently, additional regulators are emerging as supplemental mechanisms for 
hepcidin regulation, although many of these regulators are limited to one study or have been 
disputed and have not yet been classified as mainstream regulators of hepcidin. These 
regulators include hormones, growth factors and other signaling molecules.  For example, 
hormonal control of hepcidin was postulated, based on a need for increased iron during 
menstruation.  Further analysis revealed an estrogen responsive element in the hepcidin 
promoter, resulting in hepcidin suppression for increased iron in circulation [72]. However other 
studies found a positive regulation of hepcidin via estrogen [73]. Additionally, Wnt signaling has 
been suggested to positively regulate hepcidin in prostate cancer cells through a Wnt 
transcription factor responsive element in the hepcidin promoter [8].  
  In this thesis, we explore and reveal additional positive and negative regulators of 
hepcidin that regulate hepcidin locally in breast tissue.  Previous studies in prostate cells 
identified several conserved pathways for both positive (via BMP7, IL-6) and negative 
(SOSTDC1) regulation of hepcidin [8].  Overall, we identify similar conserved mechanisms as 
well as additional novel regulators of hepcidin in breast cancer, suggesting a complex regulatory 
network involving breast cancer cells and the microenvironment. 
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D.) 3D culture  
 In order to capture the full spectrum of regulatory pathways that control hepcidin in 
breast cancer, we utilize a 3D spheroid model for certain chapters of this thesis to better 
recapitulate the in vivo breast tumor architecture [74]. This model has been widely used to 
better understand cellular process and signaling pathways that 2D culture is unable to fully 
capture [75, 76]. Literature suggests that signaling pathways in 3D more accurately reflect those 
present in tumors, compared to 2D culture [76, 77]. Importantly for our studies, 3D spheroid 
systems also effectively model the metabolic pathways present within tumors [78]. There are 
many types of 3D culture conditions, but for most of our experiments, we utilize a scaffold and 
protein free system that allows the same culture conditions as 2D culture. Cells are plated in 
their normal growth media in 96-well plates coated with Poly(2-hydroxyethyl methacrylate) 
 (commonly referred to as polyHEMA), a polymer that prevents adhesion to the plate and 
promotes cell aggregation. This widely accepted 3D condition allows us to directly compare 2D 
to 3D culture without the use of exogenous basement membrane components or scaffolds, to 
examine potential changes in iron metabolism simply through modifying the cellular architecture 
and interactions [74, 79]. Additionally, aside from architectural differences that may regulate 
hepcidin simply by culturing cells in 3D, we can also examine the effects of the 
microenvironement through utilization of a 3D culture system.  These include addition of 
extracellular matrix (ECM) proteins or stromal cells to breast tumor epithelial spheroids [80].  By 
utilizing these 3D culture system modifications, it is postulated that we can better mimic breast 
tumors, including the effect of the microenvironemnt.  Ultimately, we believe a 3D model system 
will capture the full array of regulatory interactions that govern hepcidin expression including 
contributions of cytokines, extracellular matrix (ECM) and stromal cells, such as tumor 
associated fibroblasts (TAFs) [81-83].  
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E.) Primary Patient Samples 
 Another exciting component of this thesis is our ability to culture primary breast cancer 
cells from patients. Cell lines are becoming increasingly criticized models in cancer research, as 
many cell lines are suggested to have evolved over time [84]. Evidence is emerging that the 
gene expression profiles from established cancer cell lines are markedly different than tumor 
sample profiles [85]. To make up for these limitations, the use of primary cells isolated directly 
from patient tumors is becoming increasingly desired for cancer biology research [86]. 
Unfortunately, attempting to culture primary cells from patients has proven to be difficult, due to 
limited proliferation and inevitable senescence [87]. However, these limitations can be 
circumvented through utilization of a technique known as conditional reprogramming (CR) [4]. 
This technique was developed by the laboratory of Dr. Schlegel, who discovered that with the 
use of irradiated fibroblasts and Rho kinase (ROCK) inhibitor, primary epithelial cells grow 
robustly in culture.  In addition, after propagation under CR conditions, primary cells retain 
epithelial characteristics, normal differentiation potential and maintain original karyotypes [4]. It 
is our belief that, in additional to cell lines, primary breast epithelial cells will enhance our 
findings and better reflect the transformation process that causes imbalanced iron homeostasis. 
This system also allows us to have matched normal and tumor breast cells to better understand 
the mechanisms responsible for increased hepcidin expression in breast cancer cells and follow 
the iron seeking phenotype as cells transform.  
F.) Rationale 
As mentioned above, our lab has previously shown that two proteins controlling iron 
efflux are conserved in breast epithelial cells [7].  Ferroportin (FPN) allows for any excess 
intracellular iron to be readily exported from cells [88].  Hepcidin regulates FPN protein 
expression by binding to and inducing its internalization and subsequent degradation, resulting 
in decreased iron export [41].  Together, FPN and hepcidin comprise a regulatory axis to 
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maintain tight control of iron efflux. We previously demonstrated that breast cancer cells 
modulate these proteins to reduce iron efflux, ultimately favoring intracellular iron accumulation.  
Compared to non-malignant breast epithelial cells, breast cancer cells have increased hepcidin, 
which controls FPN post-translationally, through degradation [7].  These cancer specific 
alterations correspond to increased cellular levels of metabolically active iron, known as the 
labile iron pool (LIP), in breast cancer cells.   
In addition, reestablishing iron export by overexpression of FPN in breast cancer cells 
resulted in decreased growth of tumor xenografts in mice, suggesting that intracellular iron 
contributes to cellular growth [7]. Further support of modulation of iron export axis in tumor 
growth was demonstrated when hepcidin depletion in breast tumor xenografts significantly 
reduced tumor size and progression [28]. Importantly, it was also shown that low tumoral FPN 
mRNA expression is associated with a significant decrease in metastasis free survival in breast 
cancer patients [7].  Patients with favorable high FPN expression have a decreased survival rate 
if they have high tumoral hepcidin mRNA expression [7].  In addition to these modifications of 
iron proteins in breast cancer, other cancers, including colorectal, renal cell carcinoma and 
prostate cancer have increased tumoral hepcidin compared to normal samples [8, 44, 89].  FPN 
is also reduced in multiple tumor types including ovarian and prostate cancer [8, 29].  
These findings highlight the importance of FPN and hepcidin in breast cancer 
progression and prognosis.  Determining the mechanisms that regulate hepcidin are of great 
importance, as hepcidin expression ultimately controls iron efflux by facilitating FPN 
degradation.  Although hepcidin regulation has been well characterized in the liver, regulation of 
hepcidin in the breast remains poorly understood. Understanding the hepcidin regulatory 
pathways in breast cancer is of immense importance, as hepcidin and the pathways that control 
its expression, would be attractive targets to decrease excess cellular iron present in breast 
cancer cells and reduce the malignant effects that occur as a result of elevated cellular iron 
levels.   
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Figure 1-1. An overview of iron absorption and metabolism. 
Enterocytes absorb dietary iron through the combined action of ferric reductases, such as Dcytb 
and divalent metal transporter DMT1. Ferrous iron taken up by enterocytes is exported into the 
circulation by ferroportin (FPN-1). Concurrently, the Fe2+ is oxidized to Fe3+ by hephaestin 
(HEPH), which is functionally associated with FPN-1. Fe3+ is loaded on to circulating apo-TF in 
plasma. Cells take up diferric TF through the cell surface transferrin receptor (TFR1). The 
TFR1–TF–(Fe+3)2 complex is endocytosed, and iron is released from TF. Fe
3+ is reduced by the 
ferric reductase STEAP3, and Fe2+ is then transported to the cytosol by DMT1, where it enters 
the cytosolic labile iron pool (LIP). The LIP is utilized by cells for various metabolic needs. 
Excess iron is stored in ferritin or effluxed to the circulation through FPN-1. Hepatocytes 
synthesize hepcidin (HAMP) in response to systemic iron levels; the binding of hepcidin to FPN-
1 triggers FPN-1 degradation, thus inhibiting iron efflux 
(Figure from Manz and Blanchette (2016) Ann N Y Acad Sci. 1368(1): 149–161. 
Copyright © 1999 - 2017 John Wiley & Sons, Inc. All Rights Reserved) 
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Figure 1-2. Iron export is altered in breast cancer cells.  
During breast tumorigenesis, hepcidin expression is increased.  Hepcidin functions by binding to 
ferroportin, which causes its internalization and degradation.  This results in decreased iron 
export and accumulation of intracellular labile iron pool in breast cancer cells.  
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Chapter II: 
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Abstract 
Hepcidin is a secreted peptide hormone whose main function is to bind to the iron efflux pump 
ferroportin (FPN) and trigger its degradation, resulting in decreased iron export from intestinal 
enterocytes, macrophages and peripheral tissues.  Hepcidin is produced by breast epithelial 
cells for local control of iron metabolism and is elevated in breast cancer to promote 
accumulation of intracellular iron cancer cells need to proliferate. Here, we investigate the 
pathways that control increased hepcidin in breast cancer cell monolayers.  A conserved 
pathway of canonical BMPs and/or IL-6 signaling for induction of hepcidin in breast cancer cells 
was revealed and preference of these ligands for regulation of hepcidin seems to be breast cell-
line specific. Hepcidin can also be increased in normal breast epithelial cells through exogenous 
stimulation with IL-6, suggesting that iron homeostasis can be altered in normal cells through 
paracrine stimulation by exogenous sources.  Additionally, hepcidin induced by BMPs or IL-6 is 
functionally capable of FPN degradation, suggestive of a fully functional hepcidin-FPN 
regulatory axis upon induction with BMPs/IL-6. Thus, targeting of these molecular regulators of 
hepcidin may represent a promising therapeutic strategy to decrease hepcidin levels.  
Decreased hepcidin would restore intracellular iron back to normal levels, which would 
ultimately be detrimental to rapidly dividing cancer cells and halt tumor growth.  
 
Introduction 
 Since its initial discovery in the liver, hepcidin is now referred to as the master regulator 
of systemic iron homeostasis [37, 39]. As a secreted hormone peptide, hepcidin, and the 
pathways that control its expression, are considered attractive molecular targets for controlling 
some forms of anemia, where overproduction of hepcidin results in decreased iron absorption 
from duodenal enterocytes to the blood for absorption [90].  It was previously determined that 
iron levels and inflammatory pathways positively regulate hepcidin transcription in the liver [91].  
In response to increased body iron levels, bone morphogenetic proteins (BMPs) are activated 
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and upon binding to their receptors, trigger a downstream SMAD signaling cascade that leads to 
induction of hepcidin transcription in liver cells [92]. Synthesis of hepcidin was also found to be 
induced by inflammatory signals, mediated by Interleukin 6 (IL-6) and its downstream signaling 
mediator STAT3[93].  Both SMADs and STAT3 act on the human hepcidin promoter through 
direct binding to the corresponding BMP-responsive elements (BREs) and the STAT3 binding 
sites on the hepcidin promoter respectively [94].  
 Although these pathways have been widely investigated in the liver, the mechanisms 
that control hepcidin transcription in breast cancer cells are not completely known. One study, 
published in parallel to this thesis, suggested that serum hepcidin is elevated in breast cancer 
patients and that this increase is also regulated by increased iron, BMPs and IL-6 present in 
serum from BC patients [28]. Furthermore, they showed that reduction of hepatic hepcidin levels 
resulted in suppression of breast cancer progression, suggesting that circulating hepcidin is able 
to act locally on breast cancer cell ferroportin to reduce tumor iron and tumor growth.  However, 
although this study shows conserved mechanisms for increased hepatic hepcidin for systemic 
effect on breast cancer cells, it does not examine local regulation of hepcidin produced by 
breast cancer cells themselves.  Additionally, as previously mentioned, hepcidin is also elevated 
in breast cancer cells cultured in vitro compared to normal breast epithelial cells [7].  Thus, 
without systemic stimulation from exogenous sources, breast cancer cells must have some form 
of autocrine regulation of hepcidin, potentially through conserved mechanisms utilizing BMPs 
and/or IL-6.  
 It was previously shown that liver cells endogenously produce BMP ligands, which 
contributes to basal hepcidin expression via an autocrine signaling mechanism [92].  
Additionally, our lab has previously shown that prostate cancer cells endogenously produce 
BMPs and IL-6 for autocrine regulation of hepcidin, where hepcidin is also elevated compared to 
normal prostate cells [8]. Several studies have shown that breast cancer cells also have the 
ability to endogenously produce several cytokines, including BMPs and IL-6 [95, 96].  
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Endogenous BMP production in breast cancer cells has been suggested to play a role in 
disease progression [97, 98].  In addition, IL-6 was shown to be locally produced by some 
breast cancer cells, such as the highly aggressive MDA-MB-231 triple negative breast cancer 
cell line, and is thought to contribute to breast cancer growth and metastasis [99, 100].  
Endogenous production of these cytokines may act via autocrine signaling to stimulate 
downstream signaling targets for the local induction of hepcidin in breast cancer cells (Figure 2-
1).  In this chapter, we aim to elucidate the molecular pathways that control hepcidin expression 
in breast monolayer cells. 
 
Results 
IL-6 and BMPs positively regulate hepcidin in R5 and MDA-MB-231 breast cancer cells  
Due to the fact that hepcidin is induced in the liver by the BMPs and IL-6, we first 
wondered if increased expression of hepcidin through autocrine regulation by these ligands was 
conserved in breast cancer cells. To test this, we examined basal mRNA expression of IL-6 and 
several BMPs known to induce hepcidin expression.  We found moderate expression of BMP6 
and prominent IL-6 expression in the R5 breast cancer cell line, a genetically transformed cell 
line derived from normal human mammary epithelial (HME) cells with the catalytic subunit of 
telomerase, SV40 T antigen, and high levels of oncogenic H-ras [101] (Figure 2-2A).  Compared 
to normal HME cells, R5 breast cancer cells have significantly elevated IL-6 transcript, 
suggesting the IL-6 could be responsible for increased hepcidin expression in these breast 
cancer cells (Figure 2-2B). To confirm secretion of IL-6 for potential functional autocrine 
regulation of hepcidin, we examined IL-6 levels by ELISA and confirmed that R5 breast cancer 
cells secrete increased IL-6 compared to HME breast cells (Figure 2-2C).  This suggests that IL-
6 could be increased in R5 breast cancer cells for autocrine regulation of hepcidin.  
 To further confirm if IL-6 can induce hepcidin in R5 breast cancer cells, we treated R5 
cells with recombinant IL-6 (rIL-6) and examined activation of its downstream signal protein 
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(STAT3) as well as hepcidin expression following treatment.  After 24 hours of rIL-6 treatment, 
we saw activation (phosphorylation) of STAT3 at three increasing concentrations of rIL-6 (Figure 
2-3A).  Additionally, we saw ~2-fold increase in hepcidin precursor protein and increasing 
hepcidin secretion (up to ~3-fold), as detected by ELISA, with increasing concentration of rIL-6 
(Figure 2-3A and B).  Thus, we concluded that R5 breast cancer cells are able to respond to IL-
6 for induction of hepcidin.  This further supports the hypothesis that IL-6 may be a conserved 
mechanism in breast cancer cells for induction of hepcidin.  
 We also wondered if, despite modest (BMP6) or no detectable (BMP4, BMP7) 
production of BMPs, R5 breast cancer cells could respond to exogenous treatment of BMPs for 
paracrine induction of hepcidin via a conserved BMP signaling pathway (Figure 2-4A). To test 
this, we treated R5 breast cancer cells with recombinant BMPs (rBMPs) for BMP4, BMP6 and 
BMP7.  After 24 hours of rBMP treatment, we saw increased activation (phosphorylation) of 
SMAD1-5-8, the downstream signaling molecule of BMP ligands, compared to untreated cells 
(Figure 2-4B). Additionally, we saw a 2-fold increase in hepcidin protein expression with rBMP6, 
and a modest increase with BMP4 and BMP7 (Figure 2-4B).  It’s interesting to note that despite 
BMP4 activating pSMAD1-5-8 the most, it was BMP6 that seemed to have the most robust 
effect for inducing hepcidin.  BMP6 is also the most potent BMP for induction of hepcidin in the 
liver, and thus, seems to be conserved as the most potent BMP inducer of hepcidin in breast 
cancer cells. Taken together, these data suggest that both IL-6 and BMPs are conserved in R5 
breast cancer cells for positive regulation of hepcidin.  
 Next, we wanted to confirm that regulation of hepcidin by BMPs and IL-6 could be 
replicated in another breast cancer cell line that has not been genetically transformed.  Thus, we 
tested the effect of BMPs and IL-6 on inducing hepcidin utilizing a commonly used, aggressive, 
triple negative subtype cell line, the MDA-MB-231 cells. Despite activation of the downstream 
pathways of IL-6 and BMPs, we found a very modest effect on further stimulation of hepcidin 
mRNA and protein with BMPs and IL-6 (Figure 2-5A and B).  However, we observed that MDA-
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MB-231 have the highest basal hepcidin expression compared to all cell lines tested, and thus 
saturated receptors from endogenous production of BMPs and/or IL-6 may inhibit further 
exogenous stimulation (Figure 2-6A).  Since MDA-MB-231 cells have been previously 
characterized for their production of pro-inflammatory cytokines, such as IL-6, we compared IL-6 
levels across all cell lines.  We confirmed this, as MDA-MB-231 cells had very high levels of IL-
6, with ~7 fold and ~2.5 fold increase compared to R5 cells at the transcript and secreted 
protein levels respectively (Figure 2-6B and C).  Due to high endogenous production of IL-6, we 
depleted IL-6 levels with neutralizing antibody and found a significant reduction in hepcidin 
protein when IL-6 was reduced (Figure 2-6D).  This supports the hypothesis that IL-6 may be 
regulating hepcidin through an autocrine signaling loop in MDA-MB-231 breast cancer cells.  
BMPs, but not IL-6, regulate hepcidin expression MCF-7 BC cells   
 We next wanted to determine the regulation of hepcidin in a breast cancer cell line that 
does not produce endogenous IL-6.  Thus, we examined endogenous production of BMPs and 
IL-6 in an addition breast cancer cell line, the MCF-7 cells.  MCF-7 cells do not produce 
detectable levels of IL-6, unlike the R5 and MDA-MB-231 breast cancer cells, suggesting that 
something else may be responsible for increased hepcidin expression in MCF-7 breast cancer 
cells (Figure 2-7A).  Instead, we found that MCF-7 cells transcriptionally produce high levels of 
BMP4, 6 and 7, compared to MCF-10A, suggesting that a conserved BMP signaling mechanism 
may be responsible for increased hepcidin in these MCF-7 breast cancer cells (Figure 2-7A). To 
test this, we treated MCF-7 cells with rBMPs, and found that despite activation of SMAD1-5-8, 
we found no further increase in hepcidin protein expression compared to untreated cells (Figure 
2-7B).  However, since these cells are producing their own ligands, similar to MDA-MB-231 
producing high basal IL-6, we postulated additional exogenous stimulation with BMPs has a 
minimal effect on further elevating hepcidin expression.  Therefore, instead of exogenous 
addition, we reduced basal production of BMPs in MCF-7 cells, to determine if depleting BMPs 
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would result in a decrease in hepcidin expression. (Please refer to chapter 3 figures where the 
subsequent data on MCF-7 is also used for a submitted manuscript).  To test this, we treated 
MCF-7 cells with neutralizing antibodies against BMP4, 6, 7 or an isotope matched IgG and 
found that depleting BMPs resulted in decreased hepcidin expression, most prominently by 
inhibiting BMP4 and BMP6 (Figure 3-1D).  This supports the hypothesis that BMPs may be 
regulating hepcidin through an autocrine signaling loop in MCF-7 breast cancer cells. To confirm 
this effect of BMP depletion on hepcidin expression, we utilized siRNA as an additional 
approach to reduce endogenous BMP4, 6 and 7.  Similarly, we found that inhibition of BMPs by 
knock-down (KD), resulted in decreased hepcidin expression in MCF-7 breast cancer cells, 
most significantly with BMP4 and BMP6KD (~40% and ~60% respectively at the protein level) 
(Figure 3-1B and C). KD efficiencies were confirmed (Figure 3-S1D-F).   Taken together this 
suggests that the BMP pathway is conserved for positive regulation of hepcidin in MCF-7 breast 
cancer cells.  
 Despite MCF-7 lack of IL-6 production, we wanted to examine the potential role of IL-6 
from exogenous sources for paracrine induction of hepcidin via a conserved IL-6 signaling 
pathway. MCF-7 cells express IL-6 receptor (IL-6R), although at lower levels compared to the 
BMP receptors (Figure 3-S1C). Thus, we treated MCF-7 cells with recombinant IL-6 at three 
increasing concentrations and despite activation of STAT3 (Figure 3-1D), we observed a very 
slight increase of hepcidin expression (Figure 3-1D).  Therefore, we concluded that BMPs seem 
to predominately regulate hepcidin expression in MCF-7 breast cancer cells. Taken together, 
this suggests that induction of hepcidin, both autocrine and paracrine levels, seem to be cell line 
specific.  Yet, it appears that overall the IL-6 and/or BMP pathways may be conserved in the 
breast for regulation of hepcidin in a cell type specific manner.   
Normal breast epithelial cells are able to respond to IL-6 stimulation for increased 
hepcidin expression 
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 We next wondered if IL-6 regulates hepcidin expression in normal breast epithelial cells.  
Despite the fact that human mammary epithelial (HME) cells produce negligible IL-6, we 
postulated that they may respond to exogenous IL-6, as IL-6 derived from adipocytes or 
fibroblasts has been observed in breast tissue [102-104].  To test this, we treated HME cells 
with two concentrations of rIL-6 and found that STAT3 was activated, and hepcidin was 
elevated (~3 fold precursor protein; ~2 fold secreted protein) (Figure 2-8A and B).  This 
suggests that hepcidin can be induced in normal breast epithelial cells via a conserved IL-6 
signaling pathway, if an exogenous source of IL-6 is present.  
BMPs and IL-6 stimulate hepcidin induction that is functionally capable of FPN 
degradation 
 In order to determine if hepcidin induced by exogenous sources was functionally capable 
of FPN degradation, we used a fourth breast cancer cell line, the T47-D cells, which have high 
basal levels of FPN.  Thus, to determine if hepcidin was functional in these cells, we first 
confirmed that exogenous addition of BMPs and IL-6 was capable of hepcidin induction.  
Although modest, we found that treatment with all exogenous proteins resulted in increased 
hepcidin expression (Figure 2-10A).  Thus, compared to untreated cells, those with exogenous 
treatment of BMPs or IL-6 should have less FPN as a result of increased hepcidin.  As a 
positive control, we first treated T47-D cells with recombinant hepcidin and found that FPN 
expression, which normally localizes to the cell surface of T47-D cells, as analyzed by FPN 
immunofluorescence, was now internalized and punctate, suggestive of FPN degradation by 
hepcidin (Figure 2-10B). To determine if the increased hepcidin production as a result of BMPs 
or IL-6 was functional in degrading FPN, we re-treated T47-D cells with recombinant BMPs or 
IL-6 and examined FPN by immunofluorescence.  Although not as dramatic as with recombinant 
hepcidin, stimulation of hepcidin by BMPs or IL-6 resulted in reduced FPN membrane staining 
and increased intracellular localization, suggestive of FPN degradation (Figure 2-10C).  Overall, 
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this suggests that stimulation of breast cancer cells with BMPs or IL-6 increases expression of 
hepcidin, which is functionally capable of FPN degradation.   
Discussion 
 Overall, we observed that the BMP and IL-6 pathways are conserved pathways in the 
breast for induction of hepcidin.  First, we observed that R5 breast cancer cells have the ability 
to respond to exogenous stimulation of IL-6 and BMPs (most robustly with BMP6 of the three 
BMPs tested; Figure 2-3 and 2-4) for further increased hepcidin expression, which is already 
elevated compared to normal breast epithelial cells to start. This paracrine regulation may be 
extremely interesting in the context of a tumor microenvironment. It demonstrates the possibility 
of further induction of hepcidin by exogenous sources, potentially through exogenous production 
and paracrine stimulation by stromal cells, which we investigate in chapter three.  Although this 
stimulation mimics a paracrine signaling mechanism, it would be interesting to determine if 
either IL-6 or BMPs regulate the basal increased hepcidin expression present in R5 cells 
through an autocrine fashion, via production and signaling from the tumor cells themselves.  R5 
cells predominantly produce IL-6, with low endogenous production of BMPs, thus one may 
expect that IL-6 could be responsible for increased basal hepcidin expression in these cells 
compared to their HME normal counterparts (who produce negligible endogenous IL-6).  By 
depleting levels of endogenous IL-6, either with neutralizing antibodies or siRNA, we would 
expect for basal hepcidin expression to be reduced.  This would allow us to determine if IL-6 is 
regulating increased basal hepcidin expression in R5 breast cancer cells.   
 Next, we confirmed the role of IL-6 in autocrine regulation of hepcidin in the MDA-MB-
231 breast cancer cells.  Since these cells have high levels of basal hepcidin and high 
endogenous production of IL-6 (Figure 2-6), we decided to reduce basal IL-6 levels to determine 
the effect on hepcidin.  We found that depletion of IL-6 with neutralizing antibodies resulted in a 
reduction in basal hepcidin level (Figure 2-6), although our IgG isotope matched control had a 
slight effect on hepcidin as well. This confirms that IL-6 is positively regulating hepcidin in an 
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autocrine fashion in the MDA-MB-231 breast cancer cells.  Additionally, we would want to 
investigate the role of BMPs in regulation of hepcidin in these cells.  Although we did not 
observe an effect with exogenous stimulation with BMPs, perhaps depletion of endogenous 
BMPs would also result in a decrease in basal hepcidin, similar to IL-6, as MDA-MB-231 cells 
produce endogenous BMPs in addition to IL-6. 
 In the MCF-7 breast cancer cells, we found a similar, yet overall different pattern of 
hepcidin regulation in these cells, suggesting that hepcidin regulation may be cell-type specific 
in breast cancer cells.  We found that in contrast to R5 and MDA-MB-231 breast cancer cells, 
MCF-7 cells do not produce IL-6, but instead produce high levels of endogenous BMPs (Figure 
2-7 and Figure 3-1). Thus, we thought that BMPs may be regulating basal expression of 
hepcidin in MCF-7 cells.  We first tried to stimulate MCF-7 cells with exogenous BMPs, but 
realized that no further increase in hepcidin could be observed, perhaps due to saturated BMP 
receptors, as BMPs seem to regulate basal hepcidin expression in these cells (Figure 2-7). 
Instead, due to the fact that endogenous BMP and hepcidin expression are high basally, we 
used two separate methods, neutralizing antibodies and siRNA to deplete endogenous BMPs 
and found a reduction in hepcidin, most prominently with reduction in BMP6 (Figure 3-1).  This 
suggests that BMP signaling is at least partially responsible for increased basal hepcidin 
expression present in MCF-7 cells.  Interestingly, unlike the R5 cells, which produce low levels 
of BMPs but respond to exogenous BMP for hepcidin induction, MCF-7 cells respond very 
modestly to exogenous IL-6, despite having low endogenous levels (Figure 3-1). This led us to 
hypothesize that MCF-7 cells may have low IL-6 receptor expression, which was confirmed by 
examining basal IL-6R expression in MCF-7 cells (Supplementary Figure 3-S1).  Ultimately, this 
low expression could limit the robustness of a response for induction of hepcidin. However, it is 
interesting to note that we did see activation in the downstream mediator via phosphorylated 
STAT3, suggesting that MCF-7 cells were able to respond, at least in part, to IL-6 stimulation, 
despite low receptor expression.  It is also possible that levels of hepcidin in MCF-7 cells are 
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relatively high to start (and higher than R5 cells at basal level), thus activating other known 
regulatory pathways of hepcidin may not result in any further increase in hepcidin expression, 
as the promoter may not respond to further stimulation by other transcription factors. However, 
some studies in the liver have found a synergistic effect from stimulating the promoter with both 
BMPs and IL-6 [105]. It would be interesting to first deplete endogenous BMPs in MCF-7 cells 
and subsequently treat BMP depleted cells with IL-6 to see if the response to IL-6 could be 
more robust in this context. This would enable us to determine if BMPs and IL-6 could 
compensate for one another for induction of hepcidin in breast cancer cells or hint that minimal 
IL-6R expression is limiting a significant effect on hepcidin by IL-6 stimulation.  
Another interesting finding was that normal breast epithelial cells are also able to 
respond to exogenous stimulation by IL-6 (Figure 2-8).  Human mammary epithelial cells 
produce low levels of BMPs and IL-6 and have basally low levels of hepcidin.  However, upon 
exogenous stimulation with IL-6, we observed a significant increase in hepcidin expression 
(Figure 2-8).  It would be interesting if exogenous stimulation by BMPs, specifically BMP6, 
would also result in similar hepcidin induction, as this would suggest that normal breast cells are 
able to respond to exogenous stimulation of BMPs and/or IL-6 for resulting increase in hepcidin 
expression. It would also be of importance to determine if this increase hepcidin from 
exogenous IL-6 stimulation is functional.  One may expect FPN expression to be reduced and 
labile iron pool (LIP) to be increased as a result of increased hepcidin expression in stimulated 
HME cells.  If the LIP is increased, it would be interesting to see if the growth rate of these cells 
would be increased as a result of increased intracellular iron. This would demonstrate that 
proliferation rates in normal cells could be increased directly as a result of stimulating hepcidin 
expression via IL-6 (and possibly BMPs).   
 We also examined the functionality of hepcidin induced by BMPs or IL-6. To do this, we 
used the T47-D breast cancer cells, a cell line that has prominent expression of FPN. Although 
induction of hepcidin in T47-D cells by BMPs or IL-6 wasn’t robust, there was still enough of an 
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increase to see an effect on FPN (Figure 2-9). Although FPN degradation was not as dramatic 
as with recombinant hepcidin, there seemed to be a definite change in localization of FPN when 
hepcidin was stimulated with BMPs or IL-6, from cell surface, to more intracellular and punctate 
staining when hepcidin was induced exogenously. It would be interesting to see if this effect 
could be more enhanced if the experiment was carried out for a longer period of time, or if the 
addition of BMPs and IL-6 together could enhance the effect on FPN degradation.   
 Overall, we examined the role of BMPs and IL-6 in regulation of hepcidin in four 
separate breast cancer cell lines.  We observed that different breast cancer cell lines have 
varying basal expression of BMPs and IL-6 and respond to exogenous BMP and IL-6 differently. 
It would be worth examining the role of BMPs and IL-6 in additional breast cancer lines of 
different molecular subtypes (ER, PR, HER2 status) to determine if a pattern of preferential 
regulation by BMPs or IL-6 exists by subtype or if it may be selective in a more random fashion.  
Ultimately, by understanding the mechanisms responsible for increased hepcidin in breast 
cancer, we hope to unveil molecular targets in hopes of reducing hepcidin expression in breast 
cancer cells. By targeting molecular regulators with the goal of depleting hepcidin, we hope that 
excess intracellular iron will be exported from cells and proliferation of breast cancer cells will be 
reduced.  
Materials and Methods 
Cell Line Culture 
MCF-7, MCF-10A and MDA-MB-231 cells were obtained from the Wake Forest University 
Comprehensive Cancer Center Tissue Culture Core facility.  MCF-10A and MCF-7 were verified 
by ATCC cell authentication testing service. HME cells were purchased from Lonza.  HME cells 
transduced with h-TERT, SV40 T antigen, and high levels of H-ras are termed R5 cells here and 
were a gift from the laboratory of R. Weinberg [101]. T47-D cells were obtained from ATCC. 
MCF-7 and MDA-MB-231 cells were cultured in Dulbecco’s minimal essential medium (DMEM)–
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F12 (Gibco) supplemented with 10% FBS (Benchmark). MCF-10A and HME cells were cultured 
in Mammary Epithelial Growth medium (MEGM) bullet kit (Lonza catalog #CC-3150). MCF-10A 
media was supplemented with 100ug/ml cholera toxin (Sigma).  T47-D cells were cultured in 
RPMI-1640 supplemented with 10% FBS and 10μg/mL human insulin (Life Technologies). All 
cells were maintained at 37°C in a humidified atmosphere containing 5% CO2.  
 
Neutralizing antibody and recombinant protein treatments 
All treatments were added to corresponding normal growth media (without serum) for 24 hours.  
Neutralizing antibodies (R&D systems) against IL-6 or isotope-matched IgG were used at 1 or 3 
ug/mL.  Human recombinant IL-6, BMP4, BMP6 or BMP7 (R&D systems) were used at 50, 100 or 
200ng/mL. Human recombinant Hepcidin (Peptides International) was used at 800nM.  
 
Real-time qPCR.  
RNA was isolated and purified from cells using High Pure RNA Isolation Kit (Roche Diagnostics) 
following the manufacturer’s instructions. Oligo(dT) primer was used in cDNA synthesis. Briefly, 
200–400 ng of RNA was reverse transcribed in a total volume of 50 μl with a reverse 
transcription reagents kit (Applied Biosystems). To make a standard curve, serial dilutions of 
RNA from one sample were added to the RT reaction. Aliquots (2 μl) of cDNA were added to a 
18 μl reaction mixture containing 10 μlof 2× SYBR® Green PCR Master Mix (BioRad) and 400 
nm primers. The reaction included primer sequences specific to IL-6, BMP2, BMP4, BMP6, 
BMP7, hepcidin, ferroportin or β-actin depending on the experiments described. See 
Supplemental Table 3-S2 for primer sequences. Absence of DNA contamination was confirmed 
by performing PCR from cDNA without reverse transcriptase.  
Western Blots   
Samples were lysed in 1X RIPA buffer in the presence of protease and phosphatase inhibitors 
(Roche Diagnostics, Basel, Switzerland), were reduced with 10 mM β-mercaptoethanol and 
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proteins separated by SDS-PAGE. Western blots were probed with antibodies to phospho-
Smad-1/5/8 (Cell Signaling), total Smad-5 (Cell signaling), Phospho-Smad2/3 (Cell Signaling), 
total-Smad2 (Cell Signaling), Phospho-STAT3 (Cell Signaling), Total STAT3 (Cell Signaling), 
hepcidin (Fitzgerald) or β-actin (Abcam). Western blots were quantified with Image J. 
Phosphorylated blots were quantified by normalization to corresponding total protein.  Hepcidin 
blots were quantified by normalization to β-actin. 
ELISA analysis for secreted IL-6 and Hepcidin  
Secreted IL-6 was measured in conditioned growth media from HME and R5 cells using an IL-6 
Human ELISA kit from R&D systems and following manufacturers’ protocol. Secreted hepcidin 
was measured in conditioned growth media following 24 hours of IL-6, BMP4, BMP6 or BMP7 
recombinant protein treatment using a Hepcidin-25 ELISA kit from Bachem Americas, Inc. and 
following manufacturers’ protocol.  
Immunofluorescence 
T47-D cells were plated in 8-chamber slides and upon exogenous stimulation with BMPs or IL-6 
for 24 hours, cells were fixed with 4% formaldehyde for 15 minutes and blocked with 5% BSA at 
4°C overnight. Anti-human ferroportin (Amgen-38C8) was applied for one hour followed by 
1:800 dilutions of rhodamine-green conjugated goat anti-human secondary antibody (Jackson 
ImmunoResearch).  Slides were mounted with ProLong Gold anti-fade reagent (Invitrogen, 
Carlsbad, CA, USA). Images were acquired using a fluorescent inverted microscope (Zeiss Axio 
Vert.A1). 
Statistical analysis 
 
Statistical analyses were performed using Excel and are reported as the mean ± standard 
deviation.  Error bars represent standard deviation. Unless otherwise noted, significant 
differences between control and treatment groups were determined using two-tailed unpaired 
Student’s t tests. 
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Figure 2-1. Regulation of hepcidin in the liver via BMPs and IL-6. 
Previous studies have demonstrated that hepcidin is regulated in the liver transcriptionally by 
BMPs and IL-6. Each ligand binds to their respective receptor activating its corresponding 
downstream signal cascade leading to activation by phosphorylation of STAT3 and/or SMAD1-
5-8/SMAD4 for IL-6 or BMP respectively.  These transcription factors translocate to the nucleus 
where they bind to their respective responsive elements on the hepcidin promoter to trigger 
transcriptional activation of the hepcidin gene.  
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Figure 2-2. R5 breast cancer cells have increased IL-6 expression compared to normal 
human mammary epithelial cells. (A) Chart summary from RT-qPCR analysis of BMP4, 
BMP6, BMP7, IL-6, Ferroportin and Hepcidin mRNA (normalized to β-actin) in R5 breast cancer 
cells. (-) denotes no detectable expression, (+) denotes minimal transcript levels, (++) denotes 
moderate/high expression levels. (B) RT-qPCR of IL-6 (normalized to β-actin) comparing basal 
levels of IL-6 in R5 breast cancer cells and HME normal breast cells. (C) IL-6 ELISA for R5 and 
HME cells after 48 hours of secretion in normal growth media.  
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Figure 2-3. Hepcidin expression and secretion is increased and STAT3 is activated with 
exogenous IL-6 treatment in R5 Breast Cancer Cells. 
(A) Western blot analysis of phosphorylated STAT3 (pSTAT3), total STAT3 (tSTAT3), pro-
hepcidin and β-actin after 24 hours of rIL-6 treatment in R5 breast cancer cells. (B) Secreted 
Hepcidin, as detected by ELISA (Bachem) 24 hours following rIL-6 treatment in R5 breast 
cancer cells.  
 
34 
 
 
 
Figure 2-4. Exogenous BMPs positively regulate hepcidin expression in R5 BC cells. 
(A) Chart summary from RT-qPCR analysis of BMP2, BMP4, BMP6, BMP7, IL-6, Ferroportin 
and Hepcidin (normalized to β-actin) in R5 breast cancer cells. (-) denotes no detectable 
expression, (+) denotes minimal transcript levels, (++) denotes moderate/high expression 
levels. (B) Western blot analysis of phosphorylated SMAD1-5-8, pro-hepcidin and β-actin 
following treatment with recombinant BMP-4, -6 or -7 for 24 hours in R5 breast cancer cells.  
 
 
 
 
 
35 
 
 
Figure 2-5. Exogenous BMPs and IL-6 have a limited effect on induction of hepcidin in 
MDA-MB-231 breast cancer cells. 
(A) RT-qPCR of hepcidin (normalized to β-actin) and (B) Western blot of phosphorylated 
STAT3, total STAT3, pro-hepcidin and β-actin following recombinant BMP and IL-6 treatment for 
24 hours in MDA-MB-231 cells.  
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Figure 2-6. Depletion of endogenous IL-6 results in decreased hepcidin expression in 
MDA-MB-231 breast cancer cells.  
(A) Western blot analysis of basal pro-hepcidin and Ponceau stain from R5, HME, MCF7, MCF-
10A, MDA-MB-231 breast cells. (B) RT-qPCR of endogenous IL-6 mRNA (normalized to β-
actin) from R5, HME, MCF7, MCF-10A, MDA-MB-231 breast cells. (C) ELISA analysis for 
secreted IL-6 levels in HME, R5 and MDA-MB-231 breast cells. (D) Western blot analysis of 
pro-hepcidin and β-actin following treatment with neutralizing antibodies against IL-6 (1=1μg/ml 
and 3=3μg/ml), IgG control (3μg/ml) or no treatment (NT) for 24 hours in MDA-MB-231 breast 
cancer cells. 
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Figure 2-7. MCF-7 BC cells have no further induction of hepcidin with exogenous BMP 
treatment. 
(A) Chart summary from RT-qPCR analysis of BMP4, BMP6, BMP7, IL-6 and Hepcidin mRNA 
(normalized to β-actin) in MCF-7 breast cancer cells. (-) denotes no detectable expression, (+) 
denotes minimal transcript levels, (++) denotes moderate/high expression levels.  (B) Western 
blot analysis of phosphorylated SMAD1-5-8, total SMAD5, pro-hepcidin and β-actin following 
treatment with recombinant BMP-4, -6 or -7 for 24 hours in MCF-7 breast cancer cells. 
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Figure 2-8. Normal breast epithelial cells (HME) can be stimulated exogenously with IL-6 
for induction of Hepcidin. 
(A) Western blot analysis of phosphorylated STAT3, total STAT3, pro-hepcidin and β-actin after 
24 hours of rIL-6 treatment in HME normal breast cells. (B) Secreted Hepcidin, as detected by 
ELISA (Bachem) 24 hours following rIL-6 treatment in HME cells.  
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Figure 2-9. T47-D breast cancer cells respond to exogenous BMPs and IL-6 for induction 
of hepcidin that is functional.  
(A) Western blot of phosphorylated STAT3 (pSTAT3), phosphorylated SMAD1-5-8, pro-hepcidin 
and β-actin following recombinant IL-6 treatment (0, 100, 200ng/mL) or recombinant BMP4, 6, 
or 7 treatment (0, 100, 200ng/mL) respectively in T47-D cells for 24 hours. (B) 
Immunofluorescence of FPN following 24 hours of 800nM recombinant Hepcidin treatment.     
(C) Immunofluorescence of FPN following 24 hours of 200ng/mL of rBMP4, rBMP6, rBMP7 or 
rIL-6.  
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Abstract 
Hepcidin is a peptide hormone that negatively regulates iron efflux and plays an important role 
in controlling the growth of breast tumors.  In patients with breast cancer, the combined 
expression of hepcidin and its receptor, ferroportin, predict disease outcome.  However, 
mechanisms that control hepcidin expression in breast cancer cells remain largely unknown.  
Here we use three-dimensional breast cancer spheroids derived from cell lines and breast 
cancer patients to probe mechanisms of hepcidin regulation in breast cancer.  We observe that 
the extent of hepcidin induction and pathways of its regulation are markedly changed in breast 
cancer cells grown in three dimensions.  In monolayer culture, BMPs, particularly BMP6, 
regulate hepcidin transcription.  When breast cancer cells are grown as spheroids, there is a 10-
22 fold induction in hepcidin.  Microarray analysis, combined with knockdown experiments, 
reveal that GDF-15 is the primary mediator of this change.  This increase in hepcidin as breast 
cells develop a three-dimensional architecture increases intracellular iron, as indicated by an 
increase in the iron storage protein ferritin and a decrease in expression of ferroportin.  
Immunohistochemical staining of human breast tumors confirms that both GDF-15 and hepcidin 
are expressed in breast cancer specimens.  Further, levels of GDF-15 are significantly 
correlated with levels of hepcidin at both the mRNA and protein level in patient samples, 
consistent with a role for GDF-15 in control of hepcidin in human breast tumors.  Inclusion of 
tumor-associated fibroblasts in breast cancer spheroids leads to a further induction of hepcidin.  
This induction is mediated by fibroblast-dependent secretion of IL6.   Breast cancer cells grown 
as spheroids are uniquely receptive to IL-6-dependent induction of hepcidin by tumor-
associated fibroblasts, since IL-6 does not induce hepcidin in cells grown as monolayers.  
Collectively, our results suggest a new paradigm for tumor-mediated control of iron through the 
control of hepcidin by tumor architecture and the breast tumor microenvironment. 
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Introduction 
 Enhanced acquisition and retention of iron is a hallmark of breast cancer.  This 
metabolic alteration results from changes in proteins of iron metabolism that increase iron 
uptake, alter iron storage, and/or reduce iron efflux:  for example, transferrin receptor 1 (TfR1), 
the receptor that mediates uptake of transferrin-bound iron and the major iron importer cells, is 
frequently upregulated in breast cancer  [1-3], as is IRP2, a master regulator of intracellular iron  
[4].  Conversely, ferroportin, an iron efflux pump, is downregulated in breast cancer cells and 
patient tissues.  [5, 6].   
 Hepcidin, a peptide hormone that binds to ferroportin and triggers its degradation  [7], 
plays an important role in breast cancer.  Whereas the expression of ferroportin is down-
regulated in breast cancer, expression of hepcidin is upregulated  [5, 6]. Hepcidin secreted by 
breast cancer cells binds to ferroportin and initiates ferroportin degradation, thus blocking iron 
efflux and increasing iron retention  [5, 6].  Knockdown of hepcidin in breast tumor cells inhibits 
growth of breast tumor xenografts, indicating that hepcidin produced by tumor cells makes an 
important contribution to tumor growth through an autocrine/paracrine loop  [6].  Further, the 
combined expression profile of ferroportin and hepcidin is a powerful predictor of survival after 
mastectomy for women with breast cancer  [5].  Thus, the ferroportin/hepcidin regulatory axis 
has significant impact on tumor growth and disease progression in breast cancer patients.   
In addition to its role in breast cancer, hepcidin is involved in systemic iron homeostasis: 
hepcidin synthesized in the liver plays a critical role in controlling systemic iron trafficking by 
regulating ferroportin in intestinal cells, macrophages, and hepatocytes, and thus determining 
the delivery of iron to the circulation  [8-10]). In the liver, numerous laboratories have shown that 
hepcidin is controlled transcriptionally by BMPs, principally BMP6  [11, 12], as well as by 
inflammatory cytokines such as IL-6 that increase transcription of hepcidin through a STAT3-
mediated pathway  [13].     
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 In breast cancer, however, the pathways of hepcidin regulation are poorly understood.  
Here, we probe mechanisms of hepcidin regulation in breast tumors using both two-dimensional 
and, to better recapitulate tissue architecture, three-dimensional (3D) cell culture  [14, 15]  [16-
18].  We also include tumor-associated fibroblasts in these three dimensional structures to 
facilitate study of the interactions that occur between the different cell types that are constituents 
of the tumor microenvironment.  Further, in addition to breast cancer established cell lines, we 
use patient-derived cells that have been conditionally reprogrammed [19] to enable us to use 
breast cancer epithelial cells isolated directly from patients ([20]; see Materials and Methods).  
We report three major new findings. First, that three-dimensional culture of breast cancer cells 
uncovers a novel mechanism of hepcidin regulation involving GDF-15 secreted by breast 
epithelial cells.  Second, that IL-6 derived from tumor fibroblasts further augments hepcidin 
secretion from breast cancer cells, implicating the tumor stroma in hepcidin regulation.  Third, 
that the spatial organization of tumor cells alters responses to extracellular cues and activates 
additional pathways of hepcidin induction. These studies suggest a new paradigm for tumor-
mediated control of iron through the control of hepcidin by tumor architecture and the breast 
tumor microenvironment. 
 
Results 
 
BMP6 plays a major role in hepcidin induction in MCF7 breast cancer cells 
 To investigate pathways that control hepcidin expression in breast cancer (BC), we 
initially examined MCF-7 cells, a well-studied breast cancer cell line [106].  We confirmed that 
as previously described [7], MCF-7 cells grown under conventional tissue culture conditions 
exhibited increased hepcidin compared to non-tumorigenic MCF-10A breast epithelial cells 
(Supplementary Figure 3-S1A and B), thus modeling the increased hepcidin seen in breast 
cancer.   
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 We first considered the contribution of bone morphogenetic proteins (BMPs) and 
interleukin 6 (IL-6) to hepcidin regulation in breast cancer cells, since these pathways regulate 
hepcidin transcription in the liver through activation of SMAD and STAT3 signaling pathways, 
respectively [92, 93].  Measurement of endogenous transcript levels revealed that MCF-7 cells 
had higher expression of several BMPs implicated in control of hepcidin than MCF-10A cells, 
particularly BMPs-4, 6 and 7 (Figure 3-1A and Supplementary Table 3-S1).  Additionally, MCF-7 
cells expressed BMP receptors required for downstream BMP signaling (Supplementary Figure 
3-S1C).   
 To directly test the role of BMPs in hepcidin regulation, we depleted endogenous BMPs 
with siRNA and assessed the effect on hepcidin.  Knockdown of BMPs was efficient (60-95%) 
(Supplementary Figure 3-S1 D-F).  Although depletion of all three BMPs reduced hepcidin 
(Figure 3-1B and C), knockdown of BMP6 resulted in a more pronounced decrease in hepcidin 
than knockdown of BMP4 or BMP7 when assessed at both the transcript and protein level 
(Figure 3-1B and C).  siRNA-mediated inhibition of BMP6 decreased hepcidin to approximately 
the level seen in MCF10A cells.  Antibodies directed at BMPs were also effective at reducing 
hepcidin, particularly anti-BMP-6, and to a lesser extent, anti-BMP4 (Figure 3-1D).  We next 
investigated the role of IL-6 and the STAT3 signal transduction pathway to regulation of 
hepcidin in MCF7 cells.  Although IL-6 transcripts were non-detectable (Supplementary Table 3-
S1), MCF-7 cells expressed IL-6 receptor (Supplemental Figure 3-S1C).  Further, alternative 
activators of STAT3 signaling such as IL-1, IL-5, interferons or epidermal growth factor (EGF) 
have been described [107-110], and it was possible that these might trigger STAT3 activation 
and increase hepcidin synthesis.  We therefore treated MCF-7 cells with recombinant IL-6 and 
measured effects on activation of STAT3 and hepcidin.  Although STAT3 was successfully 
activated by IL-6 under these conditions, there was no corresponding induction of hepcidin 
(Figure 3-1E). Taken together, these results suggest that among previously identified regulators 
of hepcidin, BMPs, particularly BMP6, play a predominant role in MCF-7 breast cancer cells.  
45 
 
Hepcidin is dramatically induced in breast cancer spheroids 
 Recent results have suggested that three-dimensional (3D) culture may be useful for 
studying metabolic changes in cancer, particularly breast cancer [111, 112].  To test whether 
additional pathways regulating hepcidin might be uncovered using three-dimensional culture, we 
grew MCF-7 breast cancer cells and the non-tumorigenic MCF-10A breast cell line as three-
dimensional spheroids.  Cells were plated in wells coated with poly(2-hydroxy-ethyl 
methacrylate)(polyHEMA), which prevents cell adhesion and fosters the spontaneous 
aggregation of cells into multicellular spheroids, as previously described [113].  As shown in 
Figure 3-2A, under these conditions both MCF-10A non-tumor and MCF-7 tumor cells formed 
viable spheroids as demonstrated by calcein-AM staining.   
 We measured hepcidin levels in MCF-10A and MCF-7 cells grown under these 3D 
culture conditions and compared them to hepcidin synthesized by cells grown in monolayers.   
As expected, hepcidin expression was increased in MCF-7 spheroids when compared to MCF-
10A spheroids (Figure 3-2B and E). Strikingly, when levels of expression of hepcidin in cells 
grown under two and three dimensional culture conditions were compared, there was a 15 fold 
increase in hepcidin mRNA and 6-7 fold induction of hepcidin protein in MCF-7 cells grown in 
3D (Figure 3-2C and F).  This difference was not seen in MCF-10A cells, which exhibited similar 
levels of hepcidin under both two and three dimensional culture conditions (Figure 3-2D and G).  
Normal mammary epithelial cells (HME) similarly exhibited no increase in hepcidin when grown 
under 3D culture conditions (Supplemental Figure 3-S1G).   
 
Hepcidin is induced in breast cancer spheroids prepared from patient cells 
 To confirm the selective induction of hepcidin in breast cancer spheroids, we next turned 
to primary breast epithelial cells.  Breast cancer cells were isolated directly from breast tumors.  
At the same time, non-malignant breast epithelial cells were obtained from normal adjacent 
tissue to serve as patient-matched controls. Both malignant and non-malignant epithelial cells 
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were expanded on irradiated fibroblast feeder layers and re-plated in the absence of feeder 
layers prior to initiating experiments (detailed methodology is provided in Materials and Methods 
[114]). Cells exhibited typical epithelial markers, including E-cadherin and pan-cytokeratin 
(Supplementary Figure 3-S2A and B).  Vimentin, a mesenchymal marker, was not expressed 
(Supplementary Figure 3-S2A). Tumor cells expressed higher levels of N-cadherin, a protein 
associated with breast cancer cell motility and invasion [115], than non-cancer epithelial cells 
isolated from the same patient (Supplementary Figure 3-S2A).    
 We then measured hepcidin levels in these patient-derived normal and tumor cells.   
Tumor cells expressed increased levels of hepcidin transcripts when compared to normal cells 
under both monolayer and 3D culture conditions (Supplementary Figure 3-2C and D).  As we 
had observed in MCF-10A and MCF-7 cells, the difference in hepcidin expression was 
particularly pronounced in cells grown as spheroids.  We also examined the expression of 
hepcidin using immunofluorescent staining.   Consistent with changes observed at the mRNA 
level, there was a substantial increase in hepcidin in tumor cells (Figure 3-3A).  This was 
accompanied by a decrease in ferroportin in tumor spheroids compared to spheroids from 
normal cells (Figure 3-3A), suggesting that hepcidin produced by spheroids is functional in 
targeting ferroportin for degradation.  To confirm the functionality of hepcidin in breast tumor 
spheroids, we treated cells with two different anti-hepcidin antibodies and assessed the 
consequences of this treatment on levels of ferroportin.  As expected, blockade of hepcidin by 
anti-hepcidin antibodies increased ferroportin, indicating that hepcidin synthesized by these 
cells exerts its expected biological activity (Figure 3-3B). 
 Next, we compared the effects of 3D culture on hepcidin in breast cancer and normal 
cells.  Using primary breast tumor spheroids derived from four separate breast cancer patients 
(Table 3-1), we observed a marked hepcidin induction in 3D culture compared to 2D (Figure 3-
3C and Supplementary Figure 3-S2 E-H), with increases in transcript levels ranging from 10 to 
22 fold.  In contrast to MCF10A cells, which did not increase synthesis of hepcidin when 
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cultured in 3D (Figure 3-2D and G), hepcidin was also induced in spheroids from normal cells, 
albeit at lower levels than in tumor cells (~3.5 fold transcriptionally) (Figure 3-3C).   
 To assess whether the increase in hepcidin observed in 3D cultures of tumor cells was 
associated with changes in intracellular iron, we measured levels of ferritin.  Ferritin is an iron 
storage protein composed of H and L subunit types [116].  Because levels of ferritin are post-
transcriptionally increased by iron [117-119], it is frequently used as a surrogate marker for 
intracellular iron [41, 120].  We anticipated that increased hepcidin would lead to decreased 
ferroportin, thus reducing iron efflux and increasing intracellular iron and ferritin.  As shown in 
Figure 3-3E, expression of both ferritin H and L subunits was indeed increased from 2D to 3D 
culture in patient tumor cells, suggesting that the increased levels of hepcidin seen in tumor 
spheroids contributes to a phenotype of iron retention.   
BMPs and IL-6 make modest contributions to hepcidin induction in breast cancer 
spheroids 
 We next sought to determine the regulatory pathways responsible for hepcidin induction 
in breast cancer spheroids.  As seen with monolayer cells, measurement of transcript levels 
revealed that BMPs, particularly BMP-4, 6 and 7, were basally expressed in MCF-7 spheroids 
and expression was increased compared to MCF-10A spheroids (Supplementary Figure 3-S3 
A-D).  Additionally, MCF-7 spheroids expressed BMP receptors, and BMP receptor expression 
was enhanced in 3D culture compared to monolayer culture (Supplementary Figure 3-S3E).  In 
contrast, and consistent with monolayer cells, expression of IL-6 was not observed in MCF-7 
spheroids (Supplementary Figure 3-S3D). 
 To test the contribution of BMPs and IL-6 in regulation of hepcidin synthesis in 
spheroids, we first reduced levels of endogenous BMPs 4, 6 and 7 using siRNA (Supplementary 
Fig 3-S3 F-H) and assessed effects on hepcidin expression.  Depletion of BMPs reduced 
hepcidin expression in MCF-7 spheroids (Figure 3-4A and 3-4B); depletion of BMP6 had the 
most pronounced effect, resulting in an approximate reduction of 30-35% in hepcidin transcripts 
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and protein compared to non-targeting control (NTC).  Similar to what we had observed in 2D, 
there was no detectable expression of IL-6 or phosphorylation of STAT3 in MCF-7 spheroids 
(Figure 3-4C), and knockdown of STAT3 using siRNA only modestly reduced hepcidin 
transcripts (~20%) (Figure 3-4D).   
 
Growth Differentiation Factor 15 (GDF-15) induces hepcidin expression in BC spheroids 
through activation of SMAD 1-5-8 
 Since none of the classical regulators of hepcidin explained the 10-22 fold transcriptional 
increase in hepcidin expression seen in spheroids (Figure 3-2C and Supplemental Figure 3-S2 
E-H), we next examined differences in global gene expression between MCF-7 cells grown as 
monolayers and spheroids to search for non-canonical mechanisms that might underlie the 
induction of hepcidin in spheroids.  To assure that differences we observed were independent of 
the specific method used to induce spheroid formation, we compared gene expression profiles 
from cells grown using three different methods of 3D culture:  (1) spheroids cultured in 
polyHEMA-coated 96-well plates; (2) spheroids cultured in ultra-low attachment 96-well plates; 
and (3) spheroids cultured in 0.24% methylcellulose [78]. Hepcidin was upregulated to a similar 
extent using all three of these methods when compared to monolayer culture (Supplementary 
Figure 3-S4A).   
 Overall, from 1809 to 2117 genes were significantly differentially expressed in MCF-7 
spheroids, depending on the 3D culture condition (Supplementary Table 3-S2). Specific gene 
expression changes observed between 2D and 3D were remarkably similar using each of the 3 
methods of 3D cell culture (Table 3-2).  GAGE Pathway analysis revealed that global 
differences in gene expression profiles induced by 3D culture were similar to those previously 
described, including cell cycle, DNA replication and mismatch repair (Table 3-3) [121-123].  
Nine of the top 10 perturbed pathways were the same in all three 3D cases, although there were 
differences in their rank order (Table 3-3). 
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 To search for inducers of hepcidin, we examined genes that were most significantly 
upregulated under all three 3D culture conditions (Table 3-2).  Notable among these was GDF-
15: induction of GDF-15 ranged from 16.07 to 21.9 fold (FDR p-value p<0.009) (Table 3-2).  
Expression (Bi-weight average signal (log2)) of GDF-15 was robust, with an average expression 
level roughly equivalent to the mean of all other genes expressed in these cells (Supplementary 
Figure 3-S4 B-D).   
 Growth differentiation factor-15 (GDF-15; also called MIC-1 [124]) is a member of the 
TGF-β superfamily that is up regulated in many cancers, including breast cancer [124, 125].  
GDF-15 has previously been shown to correlate with and potentially regulate hepcidin, although 
in some contexts GDF-15 may act as an inhibitor rather than an activator of hepcidin (see 
Discussion and [63, 126-128]).  We observed that GDF-15 was increased in our breast cancer 
cell models when compared to non-cancer cells: MCF-7 spheroids had increased GDF-15 
compared to MCF-10A spheroids, as did patient tumor spheroids compared to spheroids 
derived from normal adjacent cells (Figure 3-5A and B). To confirm the induction of GDF-15 
seen in the microarray analysis, we measured GDF-15 mRNA using RT-qPCR and GDF-15 
protein using an ELISA assay in MCF-7 cells grown as monolayers or spheroids.  As 
anticipated, MCF-7 spheroids exhibited increased GDF-15 expression (transcript and secreted 
protein) relative to monolayer cultures (Figure 3-5C and D).  Increased expression of GDF-15 
was correlated with increased hepcidin expression in 3D spheroids (Figure 3-5E and F).  To 
confirm the generality of these findings, we also examined GDF-15 in patient-derived breast 
cancer cells.  Similar to MCF-7 cells, primary tumor cells also exhibited a pattern of increased 
GDF-15 expression from 2D to 3D culture (Supplementary Figure 3-S5 A and B).    
 To directly test whether GDF-15 induced hepcidin, we used siRNA to reduce levels of 
GDF-15 in BC spheroids.  We observed that efficient knock-down of GDF-15 (~85%; 
Supplementary Figure 3-S5 C and D) significantly reduced hepcidin expression at both at the 
transcript and protein levels (~70% and 40% respectively) (Figure 3-6A and B and 
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supplementary Figure 3-S5E).  Although GDF15 knockdown did not completely abrogate the 
induction of hepcidin seen in spheroids (Figure 3-6A), reducing GDF-15 had a greater inhibitory 
effect than blocking either BMP6 or STAT3 (Figure 3-4).  
 
GDF15 dependent hepcidin induction in spheroids is mediated by SMAD 1-5-8 
 Our next goal was to assess the signaling pathway linking GDF-15 to hepcidin 
production.  Although GDF-15 downstream signaling is incompletely understood, there is 
evidence that GDF-15 may utilize the SMAD pathway  [44, 45].  SMAD signaling proceeds via 
two divergent pathways:  pSMAD2-3 (TGFβ signaling) and pSMAD1-5-8 (BMP signaling)  [46].  
We assessed the activity of both these pathways in 2D versus 3D culture using a western blot 
for activated (phosphorylated) SMAD2-3 and SMAD1-5-8.  As shown in Figure 3-6C, only 
SMAD1-5-8 was activated from 2D to 3D culture of MCF-7 cells.  Further, reduction of GDF-15 
in MCF-7 spheroids using siRNA simultaneously reduced SMAD 1-5-8 activity (Figure 3-6D) 
and hepcidin synthesis (Figure 3-6A), supporting a role for SMAD 1-5-8 signaling in GDF-15-
mediated control of hepcidin transcription in spheroids.  This result prompted us to examine a 
role for GDF-15 in control of hepcidin in 2D.  As shown in Figure 3-6, hepcidin levels did not 
change following either knockdown of GDF-15 (Figure 3-6E and F and Supplementary Figure 3-
S6 A-D) or addition of exogenous GDF-15 (Supplementary Figure 3-S6E) in 2D cultures.  
Together, these data suggest that GDF-15 regulates hepcidin induction breast cancer spheroids 
selectively, and does so through the activation of a SMAD 1-5-8-dependent pathway. 
Expression of GDF-15 and hepcidin are correlated in breast cancer tissue 
 To test whether an association between GDF-15 and hepcidin was also present in 
breast cancer tissue, we first analyzed hepcidin (gene symbol HAMP) and GDF-15 (gene 
symbol GDF15) transcripts in the publicly available TCGA breast cancer dataset  [47].  Levels of 
both transcripts were significantly increased in cancer tissue (n=526) compared to normal 
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adjacent tissue (n= 61) (p<2x10-12 for GDF15, p<0.002 for HAMP) (Figure 3-7A and B). We 
divided tumors into two groups based on hepcidin expression (above or below the mean) and 
assessed GDF-15 expression in these two groups.  GDF-15 expression was significantly 
different among the high and low subdivisions of HAMP (p<0.01), with high HAMP associated 
with high GDF-15 expression (Figure 3-7C).  Similarly, when tumors were divided into two 
groups based on GDF-15 expression, high GDF-15 was significantly associated with high 
HAMP (p<0.04) (Figure 3-7D).  
 To explore the relationship between GDF-15 and hepcidin at the protein level and to 
assess whether both proteins were expressed in breast epithelial cells, we performed 
immunohistochemical analysis of tumor sections from 56 breast cancer patients.  As shown in 
Figure 3-7E, expression of both GDF-15 and hepcidin was evident in breast cancer tissue.  
Staining with pan-cytokeratin confirmed the expression of both proteins in epithelial cells.  
Expression of GDF-15 and hepcidin were also faintly evident in some surrounding stromal cells 
(Figure 3-7E). Further, as shown in Figure 3-7E and 3-7F, there was a strong positive 
correlation between GDF-15 and hepcidin in epithelial cells (R2=0.44, p<3x10-8), consistent 
with a role for GDF-15 in regulation of hepcidin in human breast tumors in vivo.  
Tumor Associated Fibroblasts Contribute to hepcidin induction via paracrine IL-6 
signaling  
 In addition to autocrine regulation of hepcidin by tumor epithelial cells themselves, we 
asked whether other cell types in the tumor microenvironment might contribute to hepcidin 
induction. In particular, we focused on tumor associated fibroblasts (TAFs), since these cells are 
known to support tumor growth through secretion of pro-inflammatory cytokines and growth 
factors  [48]. TAFs isolated from patient tumor tissue were fibroblastic in shape and expressed 
vimentin, a mesenchymal marker (Supplementary Figure 3-S7A).  When TAFs were co-cultured 
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with tumor epithelial cells (TECs), we observed a significant increase in hepcidin (Figure 3-8A 
and B).   
 We then explored the mechanism of TAF-dependent induction of hepcidin.  To test 
whether the induction of hepcidin by TAFs required direct cell contact or was mediated by a 
secreted factor, we prepared conditioned medium from TAFs and cultured TEC spheroids in this 
medium.  As shown in Figure 3-8C, an increase in hepcidin was detected when TEC spheroids 
were exposed to conditioned media (CM) from TAFs, supporting the role of a secreted factor in 
hepcidin induction. We then measured levels of known hepcidin agonists in TAFs.  We found 
that TAFs produced copious IL-6, with no detectable levels of BMP6 or GDF-15 (Supplementary 
Figure 3-S6B). Additionally, primary tumor epithelial cell (TEC) spheroids expressed IL-6 
receptor (IL-6R), suggesting their potential ability to respond to paracrine IL-6 signaling 
(Supplementary Figure 3-S7C). 
 We therefore tested whether the TAF factor that induced hepcidin was IL-6.  TEC were 
cultured in the presence of either TAFs or TAF CM and pSTAT3, the downstream signal 
activator of IL-6, was measured. As shown in Figure 3-8D, both TAFs and TAF conditioned 
medium activated STAT3.  We then directly evaluated the role of IL-6 in stimulating hepcidin by 
incubating the conditioned medium with neutralizing anti-IL-6 antibody before addition to TEC 
spheroid culture.  We found that depletion of IL-6 from CM (Supplementary Figure 3-S7D) 
significantly reduced hepcidin levels (Figure 3-8E and F).  Consistent with these results, the 
addition of recombinant IL-6 to TEC cultures stimulated hepcidin synthesis (Supplementary 
Figure 3-S7 E and F).  These results suggest that TAFs in the tumor microenvironment 
contribute to the synthesis of hepcidin in breast cancer epithelial cells through secretion of IL-6.  
A model of hepcidin regulation in breast cancer is shown in Figure 3-9.   
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Discussion 
 The significant association between iron efflux pathways and breast cancer patient 
outcome [7], as well as the role of hepcidin in breast cancer tumor growth in vivo [28] prompted 
us to investigate mechanisms of hepcidin control in breast cancer.  We used 3D culture of both 
breast cancer cell lines and patient-derived breast tumor cells to more fully explore mechanisms 
controlling hepcidin synthesis in vivo.   
Three dimensional culture is an important tool in the study of breast cancer growth and 
metabolism that can provide unique biological insights not evident in cells grown in 2D [129].  It 
has been suggested that 3D culture may more successfully predict tumor cell behavior in vivo 
than 2D models, since breast cancer cells grown in 3D exhibit a gene expression profile that 
more closely mimics human tumors than cells grown in 2D [76, 77].  3D culture is a promising 
tool for drug screening that may more accurately predict clinical success of anti-cancer drugs 
[130, 131].  In the present study, we found that BMPs, particularly BMP6, were important 
regulators of hepcidin synthesis in breast cancer cells grown in both 2D and 3D (Figure 3-1 B,C 
and Figure 3-4 A,B).  However the growth of breast cells in 3D allowed additional regulatory 
mechanisms to become evident.   
The first novel pathway of hepcidin regulation that we observed in cells grown in 3D was 
mediated by GDF-15.  GDF-15 is a member of the TGF-β superfamily that plays a broad role in 
tissue homeostasis and repair [124].  GDF-15 is induced in response to inflammation, acute 
injury or malignancy [125, 132, 133].   Serum levels of both GDF-15 and hepcidin are increased 
in patients with breast cancer [28, 125] and other malignancies [126-128].  GDF-15 may play 
multiple roles in cancer; however, studies in breast cancer cells have suggested a role of GDF-
15 in enhanced invasion as well as in maintenance of breast cancer stem cells [134, 135].  We 
observed that GDF-15 and hepcidin mRNA were both elevated in primary cells from breast 
tumor tissue compared to normal adjacent tissue (Figure 3-3 and Figure 3-5).  Further, 
immunohistochemical staining of breast cancer tissue arrays (Figure 3-7E) as well as 
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interrogation of publicly available microarray datasets from breast cancer patients (Figure 3-7 A-
D) indicated that there was a positive correlation between GDF-15 and hepcidin in breast tissue.  
Our work thus extends the known functions of GDF-15 to the local regulation of hepcidin in 
tumor tissue, representing a new role for GDF-15 in tumorigenesis.  Specifically, the 
upregulation of GDF-15 and consequent increase in hepcidin in tumor tissue may foster tumor 
growth by enhancing tumor iron retention.  The decrease in ferroportin and increase in ferritin 
we observed in tumor spheroids (Figure 3-3) is consistent with this interpretation. 
GDF-15 has previously been described as a negative regulator of hepcidin, since high 
serum levels of GDF-15 in patients with β-thalassemia were associated with suppression of 
hepatic hepcidin [63]. However, in this same study, the response of hepatoma cells to GDF-15 
in vitro was shown to be biphasic, with lower levels of GDF-15 stimulating hepcidin synthesis, 
and higher levels (≥ 10,000 pg/ml) inhibiting hepcidin [63] .  We observed that the level of GDF-
15 produced by breast cancer spheroids ranged from 100-500 pg/ml, consistent with an 
inductive effect of GDF-15 on hepcidin.   
GDF-15 and the BMPs are both members of the TGF-β superfamily.  Previous work has 
identified SMAD-1,5,8 as the regulatory pathway that mediates induction of hepcidin by BMPs in 
hepatocytes [50].  Although the receptor(s) and signaling pathways activated by GDF-15 have 
been less well studied than those that mediate BMP activity, experiments presented here 
suggest that GDF-15 and BMP6 may converge on the same downstream signaling pathway to 
induce hepcidin.   Thus we observed that pSMAD-1,5,8 was elevated from 2D to 3D culture of 
breast cancer cells,  and that both hepcidin and activated SMAD-1,5, 8 were abrogated when 
GDF-15 was decreased with siRNA (Figure 3-6).   
 The second major observation to emerge from this study is that stromal cells in the 
tumor microenvironment can contribute to regulation of hepcidin synthesis in breast tumor cells. 
Stromal cells play a significant role in breast tumorigenesis and secrete factors such as TGF-β 
and IGF-1 that can directly activate pathways in tumor epithelial cells (TECs)[136] (reviewed in 
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[136], [104]).  For example, TAFs have been found to secrete CXCL12 for promotion of 
proliferation, migration and invasion of breast tumor epithelial cells [137].  We found that IL6 
secreted by TAFs significantly contributes to hepcidin synthesis (Figure 3-8).  TAFs grown in the 
absence of TECs showed minimal hepcidin expression (Figure 3-8A and B), suggesting that co-
culture induces hepcidin primarily in TECs rather than in the TAFs themselves.  Consistent with 
this interpretation, conditioned media from TAFs induced hepcidin in TECs to a similar extent as 
co-culture with TAF cells (Figure 3-8C). 
 Since IL-6 was the only ligand previously associated with induction of hepcidin that was 
produced by TAFs, and TAF-mediated induction of hepcidin could be blocked by anti-IL-6 
antibody (Figure 3-8), our experiments suggest that IL-6 is the major and perhaps only factor 
secreted by TAFs that influences hepcidin synthesis.  However a limitation of our studies is that 
we were unable to isolate TAFs from multiple patient samples.  In addition, multiple additional 
cell types populate the tumor microenvironment, including immune cells of multiple lineages 
[138]; thus, more extensive analyses may uncover additional regulators that contribute to fine-
tuning hepcidin synthesis in the tumor microenvironment.  Interestingly, although we did not 
observe secretion of GDF-15 in breast cancer TAFs (Supplementary Figure 3-S7B), GDF-15 is 
secreted by TAFs isolated from prostate tumors and promotes prostate tumorigenesis [139].  
Since hepcidin is also upregulated in prostate tumors [8], it is possible that prostate cancer, 
TAFs may contribute to hepcidin synthesis through secretion of GDF-15.  
A third observation to emerge from our studies is that an alteration in the spatial 
configuration of tumor cells is sufficient to alter responses to extracellular cues and activate 
additional pathways of hepcidin induction.  Thus, although cells grown in 2D displayed receptors 
rendering them potentially responsive to IL-6, hepcidin synthesis was not triggered by treatment 
with exogenous IL-6 in cells grown in 2D (Figure 3-1E).  In contrast, breast cancer cells grown in 
3D induced hepcidin when exposed to IL-6 (Figure 3-8 and Supplemental Figure 3-S7 E and F).  
56 
 
This result underscores the importance of spatial organization in the activation of tumor 
signaling pathways, including those that regulate iron metabolism.  
Collectively, the experiments presented here demonstrate the existence of multiple 
mechanisms that coordinately control hepcidin synthesis in breast tumor spheroids.  Studies of 
mechanisms through which tumor cells and cells in the tumor microenvironment regulate 
synthesis of hepcidin may not only uncover new pathways through which hepcidin is controlled, 
but may ultimately suggest new strategies for inhibiting local synthesis of hepcidin that can be 
used to target the metabolic dependence of tumor cells on iron.  
 
Materials & Methods 
Cell Line Culture 
MCF-7 and MCF-10A cells were obtained from the Wake Forest University Comprehensive 
Cancer Center Tissue Culture Core facility and verified by ATCC cell authentication testing 
service. HME cells were purchased from Lonza. MCF-7 cells were cultured in Dulbecco’s 
minimal essential medium (DMEM)–F12 (Gibco) supplemented with 10% FBS (Benchmark). 
MCF-10A and HME cells were cultured in Mammary Epithelial Growth medium (MEGM) bullet 
kit (Lonza catalog #CC-3150). MCF-10A media was supplemented with 100ug/ml cholera toxin 
(Sigma).  All cells were maintained at 37°C in a humidified atmosphere containing 5% CO2.  
Patient Sample Isolation 
 Tumor and adjacent non-tumor human mammary tissue was obtained under the 
approval of the Institutional Review Board of UConn Health and was de-identified. Fresh 
specimens were put into F media [4]  [3:1 v/v Ham’s F12 Nutrient Mix: Dulbecco’s Modified 
Eagle Medium (Life Technologies), 5% fetal bovine serum (Gemini Bio-Products), 0.4 μg/mL 
hydrocortisone (Stemcell Technologies), 5 μg/mL human insulin (Life Technologies), 8.4 ng/mL 
cholera toxin (Sigma), 10 ng/mL epidermal growth factor (Life Technologies), 24 μg/mL adenine 
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(Sigma), penicillin-streptomycin (Life Technologies), and 10 μmol/L Y-27632 (Tocris)], and 
placed immediately on ice. 
Primary Cell Culture  
Primary cell culture was performed using conditional reprogramming technique previously 
described [114]. Briefly, specimens were removed of excess fat, minced, and then digested in 
0.1 U/mL collagenase and 0.8 U/mL dispase (Roche) for approximately 1-2 hrs at 37˚C. The cell 
suspension was passed through a 100 μm nylon filter and centrifuged at 400 x g. The cell pellet 
was resuspended in F media and washed three more times to ensure removal of the proteases. 
For tumor associated fibroblast (TAF) culture propagation (when applicable), half of the 
resuspended cell pellet was directly plated in dishes overnight in F-media and re-fed the next 
day with F-media minus cholera toxin.  TAFs were cultured in a 37˚C humidified incubator with 
5% CO2 and 7% O2. Expanded cells were trypsinized with 0.05% trypsin and replated up to five 
passages before freezing as stocks. For tumor/adjacent normal epithelial cells, the remaining 
resuspended cell pellet was plated onto irradiated (4000 Rad) mouse NIH 3T3 fibroblasts in the 
presence of 10 μmol/L Y-27632 (Tocris) and cultured in F-media at 37˚C humidified incubator 
with 5% CO2 and 7% O2. Cells were passaged by differential trypsinization; when 
approximately 90% confluent, the cells were incubated with 0.05% trypsin (Life Technologies) to 
first remove the feeder fibroblast cells. The detached fibroblasts were aspirated and the 
remaining epithelial cells were incubated with 0.25% trypsin until detached. The cells were 
neutralized with equal volume F media, gently triturated to generate a single cell suspension, 
and centrifuged at 400 x g. The cells were resuspended in F media and passaged at 1:2 – 1:4 
ratios onto irradiated feeder cultures. NIH 3T3 fibroblasts were maintained in DMEM 
supplemented with 10% FBS and 1% Pen-Step for initial culturing before use as a feeder layer. 
For use in all experiments, primary cells were passaged directly from conditional reprogrammed 
58 
 
conditions and plated as monolayers or spheroids without 3T3 fibroblasts in F-media without Y-
27632 to re-differentiate cells for at least 2 days.  
Spheroid Culture  
24 hours before spheroid plating, U-bottom 96-Well Polystyrene Round Bottom Microwell Plates 
(Fischer Scientific) were coated with Poly(2-hydroxyethyl methacrylate) (polyHEMA) (Sigma).  
Briefly, 2.4g of polyHEMA (Sigma) was dissolved in 20mL of 70% EtOH to make a 10X stock.  A 
1X solution was prepared with 70%EtOH and 30ul per well was added. Plates were left in 
laminar flow hood overnight to ensure EtOH evaporation.  To generate spheroids, cells were 
passaged from monolayer cultures and cells were seeded at 8,000 cells/well in polyHEMA 
coated plates in corresponding normal growth media.  In some experiments, spheroids were 
plated in basal growth media containing no serum. To examine spheroid viability, 2uM calcein-
AM was added to spheroid wells and live spheroids were imaged using a fluorescent inverted 
microscope (Zeiss Axio Vert.A1).  For microarray analysis only, additional spheroid techniques 
were used, including plating 8000 cells in ultra-low attachment 96-well plates (Corning) or the 
addition of methylcellulose (0.24% total) as an aggregating agent, as previously described by 
Longati et al. [78].  
Tumor Associated Fibroblast (TAF) and Tumor Epithelial Cell (TEC) Co-Culture & 
Conditioned Media Treatments 
Tumor associated fibroblasts (TAFs) were propagated in F-media.  For conditioned media (CM) 
experiments, 90% confluent cultures were replenished with fresh F-media and allowed to 
secrete for 48 hours before removal of CM and subsequent addition of CM to TEC cultures 
(8000 cells/spheroid). For direct co-cultures, TECs were trypsinized and TAFs were trypsinized 
and irradiated (4000 rad). For co-culture spheroid generation, co-cultures were produced by 
mixing 80% TEC/20% TAF (6400/1600) or 100% TEC/20% TAF (8000/1600) in F-media 
immediately before plating as spheroids. 
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Neutralizing antibody and recombinant protein treatments 
For neutralization of BMPs, cells were treated with 1 or 3 μg/mL anti-BMP4, anti-BMP6, anti-
BMP7, (R&D Systems) or 3 μg/mL isotope-matched anti-IgG (R&D systems).  For neutralization 
of hepcidin, spheroids were treated during time of plating with 1 or 3ug/mL of anti-Hepcidin-25 
(Amgen-19D12[140]; referred to as αHep#1), anti-Hepcidin-25 (Abcam; referred to as αHep#2) 
or anti-IgG (R&D systems) for 48 hours.  For neutralization of IL-6 in TAF conditioned media, 
TAF conditioned media was collected as described above and pre-treated with 1 or 5 μg/mL 
anti-IL-6 or isotope-matched anti-IgG neutralizing antibodies (R&D Systems) for one hour before 
addition of CM to TEC spheroids. Human recombinant IL-6 (R&D Systems) was used at 2 and 
200 ng/mL. Human recombinant GDF-15 (R&D Systems) was used a 0.1, 1, 10, 100 and 200 
ng/mL. 
Real-time qPCR.  
RNA was isolated and purified from cells using High Pure RNA Isolation Kit (Roche Diagnostics) 
following the manufacturer’s instructions. Oligo(dT) primer was used in cDNA synthesis. Briefly, 
200 – 400 ng of RNA was reverse transcribed in a total volume of 50 μl with a reverse 
transcription reagents kit (Applied Biosystems, Foster City, CA, USA). To make a standard 
curve, serial dilutions of RNA from one sample were added to the RT reaction. Aliquots (2 μl) of 
cDNA were added to a 18 μl reaction mixture containing 10 μl of 2× SYBR® Green PCR Master 
Mix (Bio-Rad, Hercules, CA, USA) and 400 nm primers. See Supplemental Table 3-S2 for 
primer sequences. Absence of DNA contamination was confirmed by performing PCR from 
cDNA without reverse transcriptase.  
Western Blots   
Samples were lysed in 1X RIPA buffer in the presence of protease and phosphatase inhibitors 
(Roche Diagnostics, Basel, Switzerland), were reduced with 10 mM β-mercaptoethanol and 
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proteins separated by SDS-PAGE. Western blots were probed with antibodies to phospho-
Smad-1/5/8 (Cell Signaling), total Smad-1 (Cell signaling), Phospho-Smad2/3 (Cell Signaling), 
total-Smad2 (Cell Signaling), Phospho-STAT3 (Cell Signaling), Total STAT3 (Cell Signaling), 
hepcidin (Fitzgerald), Ferroportin (Novus Biologicals) Ferritin H [141], Ferritin L (Abcam), E-
Cadherin (Cell Signaling), N Cadherin (Cell Signaling), Vimentin (Cell Signaling), Cyclophilin B 
(Abcam) or β-actin (Abcam). Western blots were quantified with Image J normalized to loading 
control (β -actin or Cyclophilin B).  
Immunofluorescence  
Primary patient spheroids were embedded in OCT, sectioned and fixed with 4% formaldehyde 
for 15 minutes and blocked with 5% BSA at 4°C overnight. Anti-human ferroportin (Amgen-
38C8) and anti-rabbit Hepcidin (Fitzgerald) were applied for one hour followed 1:800 dilutions of 
rhodamine-green conjugated goat anti-human secondary antibody (Jackson ImmunoResearch) 
for ferroportin and Alexa-fluor 555 conjugated goat anti-rabbit IgG secondary antibody 
(Invitrogen) for hepcidin. Slides were mounted with ProLong Gold anti-fade reagent (Invitrogen, 
Carlsbad, CA, USA). Images were acquired using a fluorescent inverted microscope (Zeiss Axio 
Vert.A1). 
Immunohistochemistry 
Primary patient spheroids were embedded in OCT, sectioned and stored in -80° until IHC 
procedure.  Breast tissue microarray slides were obtained from US Biomax, Inc., (Rockville, MD, 
USA; cat# BR1503e). For both specimen types, antigen retrieval was performed using 0.05% 
citraconic anhydride (Acros Organics, Geel, Belgium) at pH 7.4 prior to immunostaining.  For 
primary patient spheroids, slides were stained with Hematoxylin and eosin or pan-cytokeratin 
(AE 1/3) (Cell Signaling Technology) with hematoxylin counterstain. Images were acquired 
using a Zeiss Axio Vert.A1 microscope with color Axio Vert.A1 camera (Carl Zeiss Microscopy 
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GmbH., Jena, Germany).  For breast tissue microarrays, slides were stained with a rabbit anti-
GDF-15 antibody (Sigma-Aldrich) or rabbit anti-Hepcidin antibody (Fitzgerald). An isotype 
matched rabbit anti-IgG was used for negative control and anti-pan keratin (Cell Signaling) was 
used to distinguish epithelial from stromal cells. Slides were counterstained with hematoxylin 
(Poly Scientific R&D Corp., Bay Shore, NY, USA). Images were acquired using a Zeiss Axio 
Scan Z1 (Carl Zeiss Microscopy GmbH., Jena, Germany). To quantify Hepcidin and GDF-15 
expression, stained microarray images were analyzed with Fiji software using reciprocal 
intensity as previously described[142]. Briefly, diaminobenzidine (DAB) signal was isolated from 
images by color deconvolution. Regions of interest were drawn around epithelial tissue 
throughout the entire tissue core. Mean DAB intensity/area was then measured in the regions of 
interest (breast epithelia). Reciprocal intensity (expressed in arbitrary units) was derived by 
subtracting the maximum intensity value from measured mean DAB intensity/area values. Two 
cores per patient were used (n=56) and one value was established per patient by normalization 
with respect to total epithelial cell area.  Patients with one or both tissue cores that were 
negative for anti-pan keratin staining were excluded from quantification analysis. For correlation 
of staining intensities between Hepcidin and GDF-15, a regression analysis was performed. 
siRNA Knock-down  
All reagents were obtained from GE Dharmacon (Lafayette, CO, USA). ON-TARGETplus 
human SMARTpools were used for siBMP4 (652; cat#: L-011221-00), siBMP6 (654; cat#; L-
021475-00), siBMP7 (655; cat#: L-011592-00), STAT3siSTAT3(6774; cat #: L-003544-00), 
siGDF-15 (9518; cat#: L-019875-00) (referred to as KD#1) and siNTC (cat#: D-001810-10-05) 
were used for knockdown experiments. ON-TARGETplus individual siRNA human siGDF-15 
was used for GDF-15 KD #2 (cat:J-019875-05). siGENOME Control siRNA was used for 
GAPDH (cat#: D-001140-01-05). Transfections were performed according to the manufacturer’s 
recommendations using Dharmafect #1 (T-2001) transfection reagent. For monolayer cells, 
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knock-down was performed for 24, 48 or 72 hours before harvesting. For spheroids, knock-
down was performed in monolayer culture for 24 hours before trypsanization of cells and 
subsequent spheroid plating.  Spheroids were harvested after 3 days, 4 days after initial siRNA 
transfection.  KD efficiencies were confirmed at time of harvest by RT-qPCR and/or by ELISA 
methods described. 
ELISA analysis for secreted GDF-15, BMP-6 and IL-6 
GDF-15 and IL-6 were measured in conditioned growth media using a GDF-15 or IL-6 Human 
ELISA kit from R&D systems and following manufacturers’ protocol.. For siRNA knock-down 
efficiency, GDF-15 was measured in serum free growth media. BMP-6 was measured in 
conditioned normal growth media using a Human BMP-6 ELISA kit from Thermo Scientific and 
following manufacturers’ protocol.  
Microarray analysis 
MCF-7 cells (monolayer and 3 different 3D culture techniques; pHEMA, mCELL and ULA 
explained above) were harvested at the day 3 time point and used as samples for microarray 
analysis. RNA was collected and purified from cell culture lysate using High Pure RNA Isolation 
Kit (Roche Diagnostics). High quality RNA was submitted to the Yale Center for Genome 
Analysis (West Haven, CT) for Affymetrix GeneChip analysis of gene expression. Three 
biological replicates from each condition were hybridized onto the Affymetrix Human 
Transcriptome Array 2.0 (HTA-2.0). Raw CEL files were checked for quality and RMA 
normalized using Affymetrix Expression Console Software (version 1.4.1.46). Three separate 
differential expression (DE) analyses were performed for each of the three spheroid culture 
techniques against monolayer culture using Affymetrix Transcriptome Analysis Software 
(version 3.0.0.466) with Probeset Annotations release 36 based on UCSC hg19. Significant DE 
up-regulated genes were generated based on transcript cluster ID’s (probesets) with criteria of 
ANOVA p value of <0.05 and a fold change greater or less than 2 fold. For compilation of top 10 
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up-regulated genes, transcript cluster ID’s were checked for uniqueness with respect to gene 
annotation.  Additionally, transcript cluster ID’s without a corresponding gene symbol or 
containing _hap (haplotype chromosomes) were discarded.  For compilation of top 10 up-
regulated genes, transcript cluster ID’s without a corresponding gene symbol or containing _hap 
(haplotype chromosomes) were discarded. 
GAGE Analysis 
The transcript cluster ID with the highest average expression per gene in each dataset was 
selected to represent the expression of that gene. Significantly perturbed KEGG (Kyoto 
Encyclopedia of Genes and Genomes,  [1]) pathways within each dataset were found using the 
Gene Set Analysis method Generally Applicable Gene-set Enrichment (GAGE), since it is 
optimized for use with both small and large datasets  [2], using the bidirectional option 
(same.dir=F) and unpaired sample setting (compare="unpaired"). 
TCGA analysis 
Lowess-normalized gene-level mRNA expression data from Agilent custom whole genome 
microarrays (TCGA, BRCA, 2012; PMID: 23000897) of primary breast cancer samples were 
uploaded on 10-24-16 from the Broad Firehose (https://gdac.broadinstitute.org/), along with 
clinical and biospeciman supporting data  [143].  For each sample, GDF-15 and HAMP 
expression was extracted.  Samples were classified as 'cancer' if the 'Sample' identifier of the 
sample barcode was 01a or 01b and samples were classified as 'normal' if the 'sample' identifier 
of the sample barcode was 11a or 11b, based on identification between the sample identifier 
and the sample type in the biospecimen data.  All statistical analyses were performed in Prism 
6.  For comparison of GDF-15 and HAMP expression, respectively, between the normal and 
cancer samples, and of GDF-15 expression between low and high HAMP cancer samples, an 
independent two-tailed t test was used.   
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Statistical analysis 
All experiments were performed at least three times using a minimum of three 
replicates/condition in each experiment. Results of representative experiments are shown in the 
figures. Statistical analyses were performed using Excel or Prism 6 (Graphpad software) and 
are reported as the mean ± standard deviation.  Error bars represent standard deviation. Unless 
otherwise noted, significant differences between control and treatment groups were determined 
using two-tailed unpaired Student’s t tests.  
 
Acknowledgements 
This work was supported in part by NCI R01CA188025 (SVT) and NCI R01CA171101 (FMT).  
We thank Li Chen and Drs. Nathaniel Dyment and David Rowe for assistance in image 
acquisition, as well as Tara L Arvedson (Amgen, Thousand Oaks, CA) for a generous gift of 
anti-ferroportin antibody. 
 
 
 
 
 
 
65 
 
 
Figure 3-1. BMPs regulate hepcidin expression in MCF-7 breast cancer cells.  
(A) RT-qPCR of BMP4, BMP6 or BMP7 mRNA (normalized to β-actin) in MCF-7 and MCF-10A 
monolayer cells. (B) Western blot analysis of pro-hepcidin and β-actin and (C) RT-qPCR of 
hepcidin mRNA (normalized to β-actin) following siRNA knock-down of non-target control 
(NTC), BMP4, BMP6, and BMP7 for 48 hours in MCF-7 cells. For statistical analysis and 
quantification samples were compared to NTC. GAPDH siRNA was used as an additional 
control in western blot analysis. (D) Western blot analysis of pro-hepcidin and β-actin after the 
addition of 1 and 3 μg/mL neutralizing antibodies against BMP4, BMP6, BMP7 or IgG (3μg/ml) 
isotope control for 48 hrs in MCF-7 cells. (E) Western blot analysis of phosporylated-STAT3 
(pSTAT3), total STAT3 (tSTAT3), pro-hepcidin, and β-actin following the addition of 
recombinant IL-6 for 24 hours in MCF-7 cells. 
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Figure 3-2. Hepcidin is increased in MCF-7 breast cancer spheroids compared to non-
tumor spheroids and is induced from 2D to 3D culture of breast cancer cells.  
(A) Phase-contrast imaging of MCF-7 and MCF-10A cells grown in 2D and 3D and fluorescent 
imaging of spheroids stained with 2μM calcein. (B-D) RT-qPCR of hepcidin mRNA (normalized 
to cyclophilin A) in MCF-7 and MCF-10A cells grown in 2D and 3D. (E-G) Western blot of pro-
hepcidin using Cyclophilin B as internal control. Scale bar: 10μm (2D), 200μm (3D) 
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Figure 3-3. Hepcidin is increased in primary patient breast cancer spheroids, degrades 
FPN and is associated with an increase in the iron storage protein ferritin. 
(A) Immunofluorescence staining of FPN (green) Hep (red) and DAPI (blue) in primary breast 
spheroid sections from patient 107 normal and tumor. (B) Western blot analysis of Ferroportin 
(FPN) and Cyclophilin B (CycloB) following 48 hours of treatment with 1 or 3 μg/mL anti-
hepcidin antibody (#1 Amgen, #2 Abcam) or isotope-matched IgG control in patient 107 
spheroids. (C) RT-qPCR of Hepcidin mRNA (normalized to Cyclophilin A) of normal adjacent 
and tumor patient breast cell monolayer vs. spheroids. (D) Western blot analysis of Ferritin H, 
Ferritin L and β-actin of patient 107 monolayer and spheroids. Scale bar 50μM (20X); 20μM 
(63X). 
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Table 3-1. Clinical characteristics of primary breast tumor samples.  
 
 
All tumor samples were de-identified at time of obtainment.  Clinical pathology was performed and recorded for each patient.  
(ER) estrogen receptor, (PR) progesterone receptor, (Her-2) human epidermal growth factor receptor 2, TNM tumor node metastasis  
 
 
 
 
 
 
Patient # 
Patient 
Age 
Tumor 
Type 
Tumor Grade 
(Nottingham) Tumor Size (I/P) 
ER 
Status PR Status 
Her-2 
Status Nodal Status TNM 
107 57 Ductal I 1.5x1.0x0.5 0/8 0/8 0 0 pT1cN0MX 
109 80 
Ductal 
Colloid 
II 2.8 x 1.1 8/8 4/8 0 0 pT2NXMX 
113 53 
Ductal 
(Left) 
I 8.5x8.0x3.8 5/8 0/8 0 0 pTisN0MX 
Lobular 
(Right) 
II 5cm 8/8 8/8 0 0 pT3N0MX 
129 65 Ductal II 2.1cm 8/8 7/8 2/3 Pos (0.56mm) micro 
FISH 1.3 
pTpN1micpMX 
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Figure 3-4. Known regulators of hepcidin have a modest effect on regulation of hepcidin 
in breast cancer spheroids. (A) RT-qPCR of Hepcidin mRNA (normalized to Cyclophilin A) 
and (B) western blot analysis of pro-hepcidin and β-actin following siRNA knock-down of non-
target control (NTC), BMP4, BMP6, and BMP7 in MCF-7 spheroids. Untreated MCF-7 cells 
grown in 2D (A) or 3D (B) were used as controls. Statistical analysis and quantification was 
normalized to non-targeting control siRNA. (C) Western blot analysis of p-STAT3, total STAT-3 
and Cyclophilin B in MCF-7 monolayer versus spheroids cultured for 3 days. (D) RT-qPCR of 
hepcidin mRNA (normalized to Cyclophilin A) following siRNA knock-down of NTC and STAT3 
in MCF-7 spheroids. For statistical analysis samples were compared to non-targeting control.  
Untreated MCF-7 2D was used as a control. 
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Table 3-2. Top 10 upregulated genes in 3D culture from monolayer vs. each of the 3 spheroid conditions from microarray 
analysis.  
Significant DE up-regulated genes were generated based on transcript cluster ID’s (probesets) with criteria of ANOVA p value of 
<0.05 and a fold change greater or less than 2 fold. (pHEMA: 1809 DE, 942 up-regulated in 3D; ULA: 2117 DE, 904 up-regulated in 
3D; mCELL: 1822 DE, 809 up-regulated in 3D) 
Transcript cluster IDs that were not annotated with a gene symbol or containing _hap (haplotype chromosomes) were excluded from 
top-10 and were as follows: TC05000962.hg.1, TC02000102.hg.1, TC10002067.hg.1, TC4_ctg9_hap1000004.hg.1 
Rank 
Fold 
Chang
e 
(linear
) 
ANOVA 
p-value 
FDR  
p-value 
Gene 
Symbol 
Description 
Fold 
Chang
e 
(linear
) 
ANOVA 
p-value 
FDR  
p-value 
Gene 
Symbol 
Description 
Fold 
Change 
(linear) 
ANOVA 
p-value 
FDR  
p-value 
Gene 
Symbol 
Description 
1 47.93 
1.79E-
07 
0.00120
6 
UGT2B15 
UDP 
glucuronosyltransferase 2 
family, polypeptide B15 
46.69 
2.92E-
07 
5.08E-
04 
UGT2B15 
UDP 
glucuronosyltransferase 2 
family, polypeptide B15 
41.34 
4.39E-
08 0.000355 UGT2B15 
UDP glucuronosyltransferase 
2 family, polypeptide B15 
2 40.23 
1.12E-
07 
0.00094
9 
UGT2B17 
UDP 
glucuronosyltransferase 2 
family, polypeptide B17 
38.24 
1.71E-
07 
4.81E-
04 
UGT2B17 
UDP 
glucuronosyltransferase 2 
family, polypeptide B17 
31.38 
2.14E-
07 0.000534 UGT2B17 
UDP glucuronosyltransferase 
2 family, polypeptide B17 
3 24.63 
0.00001
5 
0.00302
8 
MIR21 microRNA 21 27.78 
0.00000
4 
1.10E-
03 
MIR21 microRNA 21 24.11 
0.00001
8 0.002121 TNFSF10 
tumor necrosis factor (ligand) 
superfamily, member 10 
4 19.67 0.00003 
0.00384
6 
TNFSF10 
tumor necrosis factor 
(ligand) superfamily, 
member 10 
25.41 
0.00001
8 
1.77E-
03 
TNFSF10 
tumor necrosis factor 
(ligand) superfamily, 
member 10 
21.9 
0.00007
9 0.004237 GDF15 
growth differentiation factor 
15 
5 16.55 
0.00016
1 
0.00802
7 
GDF15 
growth differentiation 
factor 15 
16.07 
0.00000
2 
3.41E-
03 
GDF15 
growth differentiation factor 
15 
16.46 
0.00000
1 0.000775 MIR21 microRNA 21 
6 15.18 0.00007 
0.00152
1 
MSMB microseminoprotein, beta- 15.63 
0.00004
6 
4.23E-
04 
CMAHP 
(non-
coding) 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase, pseudogene 
16.24 
8.50E-
07 0.000534 MSMB microseminoprotein, beta- 
7 15.12 0.00009 
0.00052
5 
CMAHP 
(non-
coding) 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase, pseudogene 
15.48 
0.00007
8 
5.88E-
04 
MSMB microseminoprotein, beta- 15.86 
2.97E-
07 0.000601 
CMAHP 
(non-
coding) 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase, pseudogene 
8 13.48 
6.64E-
07 
0.00049
6 
CMAHP 
(coding) 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase, pseudogene 
14.39 
5.02E-
08 
3.02E-
04 
CMAHP 
(coding) 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase, pseudogene 
15.25 
0.00002
3 0.000534 
CMAHP 
(coding) 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase, pseudogene 
9 11.78 
3.21E-
08 
0.00354
2 
LINC01087 
long intergenic non-protein 
coding RNA 1087 
13.88 
5.14E-
07 
1.10E-
03 
TNFAIP3 
tumor necrosis factor, 
alpha-induced protein 3 
12.69 
3.92E-
07 0.002055 TNFAIP3 
tumor necrosis factor, alpha-
induced protein 3 
10 11.38 0.00001 
0.00568
4 
TNFAIP3 
tumor necrosis factor, 
alpha-induced protein 3 
13.75 
0.00002
3 
0.00315
8 
LINC0108
7 
long intergenic non-protein 
coding RNA 1087 
10.96 
2.32E-
07 0.001067 CAPN9 calpain 9 
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Table 3-3. GAGE pathway analysis for top-10 perturbed pathways from monolayer to spheroid culture of MCF-7 cells. 
 PolyHEMA Ultra-low Attachment Methylcellulose 
Rank Pathway q-value Pathway q-value Pathway q-value 
1 hsa04110 Cell cycle 1.40E-31 hsa04110 Cell cycle 1.74E-31 hsa04110 Cell cycle 9.33E-31 
2 hsa03030 DNA replication 2.34E-22 hsa03030 DNA replication 4.08E-21 hsa03030 DNA replication 1.01E-20 
3 hsa03013 RNA transport 1.39E-10 hsa03013 RNA transport 1.83E-11 
hsa03460 Fanconi anemia 
pathway 
2.12E-09 
4 hsa00240 Pyrimidine metabolism 2.74E-10 hsa00240 Pyrimidine metabolism 3.85E-10 hsa03013 RNA transport 2.12E-09 
5 
hsa03460 Fanconi anemia 
pathway 
3.86E-10 
hsa03460 Fanconi anemia 
pathway 
1.35E-09 
hsa04068 FoxO signaling 
pathway 
2.23E-09 
6 hsa03040 Spliceosome 9.00E-10 
hsa04068 FoxO signaling 
pathway 
2.16E-09 hsa00240 Pyrimidine metabolism 2.96E-09 
7 hsa04114 Oocyte meiosis 4.86E-09 hsa04114 Oocyte meiosis 1.80E-08 hsa04114 Oocyte meiosis 6.24E-08 
8 hsa03430 Mismatch repair 7.32E-09 hsa03430 Mismatch repair 2.03E-08 hsa03430 Mismatch repair 6.24E-08 
9 
hsa04068 FoxO signaling 
pathway 
2.17E-08 hsa03050 Proteasome 4.41E-08 hsa04115 p53 signaling pathway 2.09E-07 
10 hsa04115 p53 signaling pathway 1.67E-07 hsa04115 p53 signaling pathway 6.36E-08 hsa03410 Base excision repair 5.53E-07 
The transcript cluster ID from differential expression analysis with the highest average expression per gene in each dataset was 
selected to represent the expression of that gene. Significantly perturbed KEGG (Kyoto Encyclopedia of Genes and Genomes,  [1]) 
pathways within each dataset were found using the Gene Set Analysis method Generally Applicable Gene-set Enrichment (GAGE). 
Top 10 pathways and corresponding q-value are displayed for each 3D condition.  
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Figure 3-5. GDF-15 is induced in breast cancer spheroids and correlates with hepcidin 
expression.  (A-C) RT-qPCR of GDF-15 mRNA (normalized to Cyclophilin A) between (A) 
MCF-7 and MCF-10A spheroids, (B) patient 107 Tumor vs. normal adjacent tumor (normal) 
spheroids and (C) MCF-7 monolayer vs. MCF-7 spheroids.  (D) Secreted GDF-15 from 
conditioned media of MCF-7 monolayer and spheroids. (E-F) RT-qPCR of (E) GDF-15 mRNA 
(normalized to Cyclophilin A) and (F) hepcidin mRNA (normalized to Cyclophilin A) in MCF-7 
monolayer (2D) and spheroids (3D) over time. 
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Figure 3-6. GDF-15 positively regulates hepcidin via a conserved pSMAD1-5-8 pathway. 
(A) RT-qPCR of Hepcidin mRNA (normalized to Cyclophilin A) and (B) western blot analysis of 
pro-hepcidin and β-actin following knock-down using non targeting control (NTC) siRNA and 
GDF-15 siRNA (KD#1) in MCF-7 spheroids.  Untreated MCF-7 cells grown in 2D or 3D were 
used as controls. For statistical analysis, samples were compared to non-targeting control. (C) 
Western blot analysis of phosphorylated SMAD2-3, total SMAD2, phosphorylated SMAD1-5-8, 
total SMAD-1, and β-actin in MCF-7 monolayers and spheroids. (D) Western blot analysis of 
pSMAD1-5-8, tSMAD-1 and β-actin following siRNA knock-down of NTC and GDF-15 knock-
down #1. (E-F) RT-qPCR of (E) hepcidin mRNA (normalized to Cyclophilin A) and (F)GDF-15 
mRNA (normalized to Cyclophiin A) following siRNA knock-down of NTC and GDF-15 knock-
down #1 for 3 days in MCF-7 monolayer. For statistical analysis, samples were compared to 
non-targeting control. 
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Figure 3-7. Hepcidin and GDF-15 are increased and their expression is correlated in 
breast tumors. (A and B) Box plot with Tukey whisker of (A) GDF-15 and (B) HAMP mRNA 
expression (log2 transformed) in normal adjacent tissue (n=61) compared to primary tumor 
tissue (n=526) in the TCGA breast cancer dataset. (C) GDF15 transcripts in TCGA samples 
from breast cancer patients divided by HAMP expression (below and above the mean) shown 
as box and whisker plot.  (D) HAMP transcripts in TCGA samples from breast cancer patients 
divided by GDF15 expression (below and above the mean) shown as box and whisker. (E) 
Representative images of immunohistochemical staining of tumor tissue from patients with 
invasive ductal carcinoma (IDC).  Proteins stained are Hepcidin, GDF-15, Pan-Cytokeratin and 
IgG control. (F) Scatter plot displays quantification of staining of epithelial cells from tissues from 
56 BRCA patients.  A regression analysis was performed to examine correlation of staining 
intensities (R2=0.4434 p<3x10-8). 
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Figure 3-8. IL-6 secreted by tumor-associated fibroblasts (TAFs) induces hepcidin in 
breast cancer spheroids. (A) RT-qPCR of hepcidin mRNA (normalized to Cyclophilin A) in 
patient 113Lobular cells. Samples were 100% 2D tumor epithelial cells (2D TEC), 100% tumor 
epithelial cell spheroids (3D TEC), spheroids composed of a mixture of 80% TEC and 20% 
irradiated TAFs, (80% TEC +20%TAF) and 100% irradiated TAF spheroids after 3 days of 
culture. (B) Western blot analysis of pro-hepcidin and Cyclophilin B for different TEC/TAF (%) 
combinations after 3 days of spheroid culture. (C) RT-qPCR of hepcidin mRNA (normalized to 
Cyclophilin A) and (D) western blot analysis of phosphorylated and total STAT3 of primary TEC 
spheroids alone, spheroids composed of a mixture of 80% TECs and 20%TAFs, or TEC 
spheroids exposed to conditioned media (CM) from TAFs for 4 days. For statistical analysis in 
(C) samples with 20% TAF or TAF CM were compared to their respective 3D TEC sample. (E) 
RT-qPCR of hepcidin mRNA (normalized to Cyclophilin A) of patient 113Lob spheroids after the 
addition of TAF CM and IL-6 neutralizing antibody (1=1μg/mL and 5=5μg/mL) for 4 days. 
Neutralizing antibody against IgG (1 and 5 μg/mL) was used as a control. For statistical analysis 
samples were compared to TAF CM sample. (F) Western blot analysis of pro-hepcidin and β-
actin of patient 113Lob spheroids after the addition of TAF CM with or without 1μg/mL 
neutralizing antibodies against IL-6 or IgG for 4 days. 
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Figure 3-9. Working model of multiple modes of regulation of hepcidin in breast cancer 
spheroids.  
Hepcidin expression is increased in breast cancer cells relative to non-cancer cells.  (A) In MCF-
7 cells grown as 2D monolayers, BMP6 plays a dominant role in the cancer-dependent increase 
in hepcidin through activation of a SMAD1-5-8 signaling pathway. (B) In breast cancer 
spheroids, spatial control of hepcidin synthesis is exerted by GDF-15, which augments SMAD 1-
5-8 signaling to further increase hepcidin synthesis.  (C) The microenvironment is an additional 
source for increased hepcidin in breast cancer cells, in part due to production of IL-6 by tumor-
associated fibroblasts (TAFs).   
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Supplementary Figure 3-S1. BMPs regulate hepcidin expression in breast cancer cells 
and induction of hepcidin in spheroids is specific to breast cancer spheroids. 
(A) RT-qPCR of hepcidin mRNA (normalized to β-actin) and (B) western blot analysis of pro-
hepcidin and β-actin in MCF-10A and MCF-7 monolayer cells. (C) RT-qPCR of ALK2, ALK3, 
ALK6, BMPRII and IL-6R mRNA (normalized to β-actin) in MCF-7 monolayer cells. (D-F) RT-
qPCR of (D) BMP4 (E) BMP6 and (F) BMP7 mRNA following siRNA knock-down in MCF7 
monolayer cells. Samples are normalized to β-Actin and are relative to non-targeting control 
(NTC). (G) RT-qPCR of hepcidin/Cyclophilin A in human mammary epithelial (HME) cell 
monolayer and spheroids.  
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Supplementary Table 3-S1. MCF-7 cells express higher transcript levels of BMP4, 6, and 
7, but not BMP2 or IL-6 when compared to MCF-10A cells. 
 
 
 
 
 
 
 
 
 
Relative mRNA transcripts from RT-qPCR of BMP2, BMP4, BMP6, BMP7 and IL-6 mRNA 
(normalized to β-actin) in MCF-7 and MCF-10A monolayer cells. (ND) Not detected. 
 
Ligand MCF-10A MCF-7 
BMP2 9.92 1.01 
BMP4 0.06 0.98 
BMP6 0.73 1.51 
BMP7 0.0009 1.00 
IL-6 ND ND 
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Supplementary Figure 3-S2. Primary patient cells retain epithelial characteristics and 
display hepcidin induction from 2D to 3D.  
(A) Western blot analysis of patient 107 primary tumor and normal adjacent tissue for E-
cadherin, N-cadherin, Vimentin and β-actin. (B) H&E and Immunohistochemistry staining of 
Pan-Cytokeratin AE 1/3 of patient 107 primary tumor and normal adjacent tissue spheroid 
sections. (C) RT-qPCR for hepcidin mRNA (normalized to β-actin) for patient 107 primary tumor 
and normal adjacent tissue monolayer cells. (D) RT-qPCR for hepcidin mRNA (normalized to 
Cyclophilin A) for patient 107 primary tumor and NAT spheroids. (E-H) RT-qPCR for hepcidin 
mRNA (normalized to Cyclophilin A) for monolayer vs spheroids from patient (E) 109Duc, (F) 
129Duc, (G) 113Duc and (H) 113Lob tumor cells. Scale bar 100μm. 
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Supplementary Figure 3-S3. BMPs are endogenously produced in BC spheroids and are 
elevated compared to non-tumor spheroids.  
(A-C) RT-qPCR of (A) BMP4, (B) BMP6 and (C) BMP7 mRNA (normalized to Cyclophilin A) in 
MCF-7 and MCF-10A spheroids. (D) Relative mRNA transcript values from RT-qPCR of BMP4, 
BMP6, BMP7 and IL-6 mRNA (normalized to Cyclophilin A) in MCF-10A and MCF-7 spheroids. 
(E) RT-qPCR of ALK2, ALK3, ALK6, and BMPRII mRNA (normalized to Cyclophilin A) in MCF-7 
monolayer and spheroids. (F-H) RT-qPCR of (F) BMP4, (G) BMP6 and (H) BMP7 mRNA of 
non-targeting control (NTC) and siRNA knock-down in MCF-7 spheroids. Samples are 
normalized to Cyclophilin A. 
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Supplementary Figure 3-S4. Hepcidin and GDF-15 are upregulated in MCF-7 cells grown 
as spheroids independent of the method used to induce spheroid formation. 
(A) RT-qPCR of Hepcidin mRNA (normalized to Cyclophilin A) in replicate cultures of MCF-7 
cells grown as monolayers (2D), ultra-low attachment (ULA) spheroids, poly-HEMA (pHEMA) 
spheroids, or methylcellulose (mCELL) spheroids submitted for microarray analysis. (B-D) 
Scatterplot of bi-weight average signals (log2) for all microarray transcript cluster IDs of 2D 
monolayer and (B) 3D polyHEMA (C) 3D ultra-low attachment and (D) 3D methylcellulose 
samples.  Red represents genes up-regulated (up-reg) in 3D; green represents genes down-
regulated (down-reg) in 3D; gray represents genes not differentially expressed (DE). 
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Supplementary Figure 3-S5. GDF-15 is induced in 3D culture of BC spheroids and 
depletion of GDF-15 results in significant reduction of hepcidin expression.          
(A) RT-qPCR of GDF-15 mRNA(normalized to Cyclophilin A) in primary tumor monolayers vs. 
spheroids. (B) ELISA of secreted GDF-15 in primary tumor monolayers and spheroids. (C) RT-
qPCR of GDF-15 mRNA (normalized to Cyclophilin A) and (D) GDF-15 ELISA following knock-
down of GDF-15 using 2 different siRNAs (siRNA #1 and siRNA #2) compared to non-targeting 
control (NTC).  (E) RT-qPCR of Hepcidin mRNA (normalized to Cyclophilin A) for NTC, GDF-15 
siRNA#1 and siRNA#2.  
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Supplementary Figure 3-S6. GDF-15 depletion does not affect hepcidin expression in 
MCF-7 monolayer cells.   
(A-D) RT-qPCR of (A-B) Hepcidin mRNA (normalized to Cyclophilin A) and (C-D) GDF-15 
mRNA (normalized to Cyclophilin A) following knock-down using non-targeting control (NTC) 
and GDF-15 (KD #1) siRNA for (A and C) 2 days or (B and D) 4 days in MCF-7 monolayer cells. 
For statistical analysis, samples were compared to non-targeting control. (E) RT-qPCR of 
Hepcidin mRNA (normalized to β-actin) following recombinant GDF-15 treatments for 24, 48 or 
72 hours in MCF-7 monolayer cells.  
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Supplementary Figure 3-S7. Characterization of tumor associated fibroblasts (TAFs) and 
their regulation of hepcidin by IL-6.  
(A) Western blot analysis of patient 113 TAFs, TEC (ductal) and TEC (lobular) depicting 
expression of E-cadherin, N-cadherin, Vimentin and β-actin. (B) ELISA results of secreted IL-6, 
GDF-15 and BMP6 (pg/mL) from TAF conditioned media after 48 hours of secretion. ND=not 
detected based on ELISA minimum threshold (<23.4pg/mL for GDF-15, <150pg/ml for BMP6).  
(C) RT-qPCR of IL-6 receptor (IL-6R) mRNA (normalized to Cyclophilin A) for primary tumor cell 
spheroids. (D) IL-6 ELISA following neutralization of IL-6 or IgG (1=1μg/mL and 5=5μg/mL) in 
p113Tu lobular spheroids after 4 days. For statistical analysis, samples were compared to TAF 
conditioned media sample. (E-F) RT-qPCR of hepcidin mRNA (normalized to Cyclophilin A) 
after 3 days of recombinant IL-6 treatment in (E) patient 113TuLob or (F) patient 107TuDuc 
spheroids. 
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Supplementary Table 3-S2. Primer Sequences used for RT-qPCR. 
 
Gene Name Forward Primer Sequence Reverse Primer Sequence 
β-actin TTGCCGACAGGATGCAGAAGGA AGGTGGACAGCGAGGCCAGGAT 
Cyclophilin A CTGGACCCAACACAAATGGTT CCACAATATTCATGCCTTCTTTCA 
Hepcidin CTGACCAGTGGCTCTGTTTTC GAAGTGGGTGTCTCGCCTC 
BMP2 CGCAGCTTCCACCATGAAGAA CCTGAAGCTCTGCTGAGGTGATA 
BMP4 AGGAGCTTCCACCACGAAGAAC TGGAAGCCCCTTTCCCAATCAG 
BMP6 GTGAACCTGGTGGAGTACGACAA AGGTCAGAGTCTCTGTGCTGATG 
BMP7 CAGCCTGCAAGATAGCCATT GAGCAGGAAGAGATCCGATT 
IL-6 AAATGCCAGCCTGCTGACGAAC AACAACAATCTGAGGTGCCCATGCTA 
IL-6R CTCCTGCCAGTTAGCAGTCC TCTTGCCAGGTGACACTGAG 
STAT3 GGCATTCGGAAAGTATTGTCG GGTAGGCGCCTCAGTCGTATC 
GDF-15 GGTGTCGCTCCAGACCTATG GGAACCTTGAGCCCATTCCA 
ALK2 ACGATGGCTTCCACGTCTACCAG ACAGTGTAATCTGGCGAGCCAC 
ALK3 TGCTATTGCTCAGGGCACTGTC TCGGCCTTTACCAACTTGCCG 
ALK6 AGTGTCGGGACACTCCCATTC TGAACCAGCTGGCTTCCTCTGTG 
BMPRII TGACACAACACCACTCAGTCCA GCTGCTGCCTCCATCATGTTC 
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Abstract 
The extracellular matrix (ECM) is commonly modified in breast cancer to support malignancy. 
Iron metabolism is also altered in breast cancer, where iron is retained to support cancer cells 
proliferative demands.  Despite common contributions to breast cancer progression, no 
evidence exists to display a mechanistic link between the ECM an iron metabolism.  Due to the 
fact that 3D spheroid culture can reflect the cell-ECM contacts present in breast tumors and 
hepcidin induction is elevated in spheroids as displayed in chapter three, we investigated a 
potential role of the ECM on regulation of hepcidin. The ECM, specifically collagen I and IV, was 
found to repress hepcidin spheroid induction at early time points in breast cancer spheroids. 
Mechanistically, collagen reduces levels and downstream activity of GDF-15, suggesting that 
collagen may act as a storage depot for potential release of ligands in times of cellular demand 
for increased iron.  This reveals a novel relationship between the ECM and iron metabolism, 
potentially through tight control and release of positive regulators in times of hepcidin and 
subsequent iron demands.  
 
Introduction 
The extracellular matrix plays a vital role in maintaining normal breast architecture and is 
modified during breast cancer progression [144, 145]. The role of the ECM has been extensively 
studied in many cancers, including breast cancer [146-149].  Cancer cells can take advantage 
of the once organized and supportive integrity of the ECM, by breaking down and modifying the 
microenvironment to fuel its malignant potential [144, 150]. This has been shown to be a 
dynamic process in breast cancer.  First, tumor cells break down their basement membrane 
ECM, which was once there to promote normal breast tissue architecture. Following this 
breakdown, breast cancer cells increase production of ECM resulting in increased breast 
density, mainly though deposition of collagen fibers [151].  Not only can this aberrant ECM 
production support tumor cell progression through direct signaling, but it has also been 
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observed that collagen fibers are positioned in a linear arrangement to aid in breast cancer cell 
migration and intravasation out of the primary tumor site [152-154].   
3D spheroid culture has been praised for its ability to better recapitulate the cell-
extracellular matrix (ECM) interactions present within tumors that monolayer culture is unable to 
model [81]. Studies have shown that 3D spheroid culture of cancer cells show an increased 
endogenous production of several matrix proteins, such as fibronectin, compared to monolayer 
culture [78].  It is believed that matrix protein production is increased in 3D culture to serve as a 
barrier to drug diffusion, resulting in increased chemoresistance [78].  Drug resistance has been 
repeatedly observed in 3D culture and better reflects the drug resistance of tumors [155-158].  
Thus, the ECM and iron metabolism are both altered in spheroids compared to monolayer 
culture. Due to these concomitant changes, we wondered if any relationship might exist 
between the ECM and iron regulation, as both entities are known to contribute to breast cancer 
progression. Specifically, any potential role of the ECM in regulation of hepcidin has never been 
investigated. 
 Unlike MCF-7 breast cancer cells, which are known to spontaneously form spheroids in 
suspension culture, many other cancer cells require a 3D scaffold or exogenous ECM substrate, 
such as Matrigel (BD Biosciences), composed of mostly laminin and collagen IV, to assist with 
spheroid formation [79, 159, 160].   In this study, we first examine the effects of exogenous 
ECM on hepcidin expression by Matrigel addition.  An effect on hepcidin would suggest that the 
ECM is an integral component in regulation of hepcidin within the tumor microenvironment and 
would provide a greater understanding of the crosstalk between the ECM and regulation of iron 
in breast cancer.  Our findings highlight and important role of the ECM, specifically by collagen, 
in regulation of hepcidin.  Mechanistically, collagen regulation of hepcidin may be a cell 
protective mechanism through storage of GDF-15 and potentially other positive regulators of 
hepcidin.  This may involve a complex temporal relationship for iron sensing and release of 
positive regulators when a demand for hepcidin exists.  
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Results  
 
Collagen negatively regulates hepcidin in breast cancer spheroids  
 In addition to stromal cells within the tumor microenvironment as we examined in 
chapter three, we also wondered if extracellular matrix (ECM) proteins could influence hepcidin 
expression, as a direct role of ECM proteins on breast tumorigenesis is evident [144]. To test 
this, we first cultured MCF-7 spheroids in the presence of Matrigel, either 2% supplemented in 
the media or cultured directly on pure Matrigel.  We noted that 2% Matrigel resulted in more 
uniform, densely packed spheroids and those cultured on pure Matrigel were smaller and more 
numerous compared to our non-Matrigel spheroids (Figure 4-1A). All spheroids were viable as 
depicted by calcein-AM staining. We next examined hepcidin expression in these various 
spheroids and noticed a significant reduction of hepcidin in the presence of Matrigel compared 
to non-Matrigel containing spheroids (Figure 4-1B). Hepcidin transcript levels were reduced 
~50% in Matrigel containing spheroids compared to the normal 3D spheroids, yet were still 
induced compared to monolayer cell levels.  This led us to believe that the intrinsic properties of 
3D culture results in induction in our Matrigel containing spheres compared to monolayer 
culture, yet something present in the Matrigel was limiting their full induction of hepcidin.  Thus 
we hypothesized that something present in Matrigel may be negatively regulating hepcidin 
expression.  
 To test this, we examined the constituents of the growth factor reduced Matrigel we used 
in our experiments and found that according to the manufacturer (Corning), Matrigel is 
composed of 50% laminin, 30% collagen IV and 8% entactin as well as heparan sulfate 
proteoglycans.  Thus we analyzed the effects of these proteins on hepcidin expression.  We first 
started by exogenous addition of the two most highly abundant proteins in Matrigel, laminin and 
collagen IV, to our MCF-7 spheroids. We found that laminin had no effect on hepcidin 
expression, but addition of collagen IV resulted in significantly reduced hepcidin expression 
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compared to untreated spheroids at multiple concentrations (Figure 4-2 A and B).  We next 
wondered if this effect was specific to collagen IV or was an effect of collagen in general.  Thus, 
we treated MCF-7 spheroids with exogenous collagen I in addition to collagen IV and found both 
collagen proteins have a similar effect on reducing hepcidin expression in MCF-7 spheroids 
(Figure 4-2 C).  To further support these results, we also treated our primary patient breast 
cancer spheroids with collagen I and IV and again saw the same negative effect on hepcidin 
expression, in which hepcidin was even more dramatically reduced in our patient spheroids 
(Figure 4-2 D and E).  Overall we concluded that collagen I and IV negatively regulate hepcidin 
expression in breast cancer spheroids.  
Collagen potentially sequesters GDF-15 for negative regulation of hepcidin 
 Next, we elucidated the mechanism by which collagen was negatively regulating 
hepcidin.  It is known that the ECM can be a reservoir for growth factors and ligands and act as 
a storage depot of bioactive molecules for later use in times of cellular demand [161, 162].  
Thus, collagen may be repressing hepcidin induction by sequestration of ligands that positively 
regulate hepcidin in spheroids, such as GDF-15, as modeled in Figure 4-5.  Interestingly, 
previous literature suggests that prostate cancer cells secrete the unprocessed form of GDF-15 
and that it associates with the ECM for extracellular storage of GDF-15 [163]. Thus we 
hypothesized that collagen is initially sequestering GDF-15 extracellularly and preventing GDF-
15 from binding to spheroid cells and triggering its downstream signal cascade for hepcidin 
induction.  To test this, we first treated MCF-7 spheroids with collagen I or IV and found that 
levels of secreted GDF-15 in the media of spheroids was reduced in spheroids containing 
collagen compared to spheroids without collagen (Figure 4-3A).  Additionally, since our previous 
work in chapter three suggests that GDF-15 regulates hepcidin via signaling through SMAD1-5-
8, we checked activity of this pathway in the presence of collagen I or IV.  We found that in the 
presence of collagen, pSMAD1-5-8 was reduced and again resulted in decreased hepcidin 
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expression (Figure 4-3B).  Overall, this suggests that collagen could be mediating its effect of 
reducing hepcidin expression through initial sequestration of GDF-15 and subsequent reduction 
of SMAD1-5-8 activity, which is modeled in Figure 4-4.  
 
Discussion 
In this study, we found that exogenous ECM, either by Matrigel, collagen I or collagen IV 
addition, results in reduced hepcidin expression compared to spheroids not treated with 
exogenous ECM (Figure 4-1 and 4-2). Additionally, we found that secreted GDF-15 was 
reduced in the presence of collagen I or IV and that its downstream activation through pSMAD1-
5-8 was also reduced (Figure 4-3).  Thus, we postulated that collagen may be sequestering and 
binding GDF-15, as a similar mechanism has been previously described in prostate cancer cells 
[163]. However, in that study they showed that GDF-15 was secreted from prostate cancer cells 
in its precursor form and that this inactive form was sequestered and binding to the ECM for 
extracellular storage [163]. Thus it’s postulated that once the cancer cells require GDF-15, it 
could be cleaved extracellularly where it becomes free to dissociate from the ECM and trigger 
its signaling cascade on neighboring cancer cells or be secreted into serum for maintaining 
systemic levels of GDF-15. In our study, our detection methods for analyzing GDF-15 (by ELISA 
method) can detect both the precursor as well as the active forms, so it would be worthwhile to 
determine what form (precursor or mature) of GDF-15 is predominantly being secreted from 
MCF-7 spheroids.  In addition to which form is being secreted, we would next want to examine a 
potential physical binding between GDF-15 and collagen. Although GDF-15 was previously 
found to be generally associated with the ECM, a direct binding between GDF-15 and collagen 
has not been identified [163].  
Furthermore, our experiments were conducted very short term, where the spheroid may 
not need the excess GDF-15 currently being stored in the ECM. It would be interesting to 
determine if the levels of active GDF-15, and subsequent pSMAD1-5-8 signaling would increase 
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over time when GDF-15 would be needed for positive regulation of hepcidin (and thus 
increasing intracellular iron). If levels of active GDF-15 increase over time, one would also 
expect levels of hepcidin to increase over time as well. If this is a dynamic process and GDF-15 
and its subsequent signaling are increasing over time, it would be interesting to determine what 
is responsible for this shift from bound to unbound (or inactive to active) GDF-15.  If it is binding 
as a precursor, one may presume that GDF-15 would be cleaved by ECM associated pro-
convertases such as PC6 or PACE4 or matrix metalloproteinases (MMPs) such as MMP14 or 
MMP26, both of which were previously found to cleave and activate GDF-15 [164-166].  It is 
plausible that low iron is sensed in spheroid cells, leading to up-regulation of a cleavage factor 
for extracellular cleavage of GDF-15, which would result in its activation.  Upon cleavage, the 
GDF-15 would be free to trigger its downstream signaling pathway for increased hepcidin 
expression, leading to increased intracellular iron.  
In addition to further characterization between the direct relationship between collagen 
and GDF-15, we would also want to examine potential relationships between collagen and other 
positive regulators of hepcidin, such as the BMPs, as BMP2 and collagen binding has been 
previously observed [167].  Since our data demonstrates that GDF-15 and BMPs utilize the 
same pathway through pSMAD1-5-8 activation, it is possible that levels of BMPs are also 
decreased by addition of collagen and this contributes to the decrease in hepcidin observed in 
spheroids treated with collagen. It would also be interesting to determine if collagen has the 
same effect on decreasing hepcidin in monolayer culture of MCF-7 breast cancer cells.  This 
would enable us to determine if this negative effect on hepcidin by collagen is an effect specific 
to 3D structures, or a general effect of collagen scaffolds through ligand sequestration in either 
dimension.  Overall, this study demonstrated a dynamic connection between the ECM and 
hepcidin and although there is still much to be elucidated, this is the first study to reveal a 
relationship between the ECM and iron metabolism in breast cancer. Both the ECM and iron 
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metabolism are well characterized as contributors to breast cancer progression, thus 
establishing a connection between them would prove extremely impactful.  
Materials and Methods 
Cell Line Culture 
MCF-7 cells were obtained from the Wake Forest University Comprehensive Cancer Center 
Tissue Culture Core facility and verified by ATCC cell authentication testing service. MCF-7 
cells were cultured in Dulbecco’s minimal essential medium (DMEM)–F12 (Gibco) 
supplemented with 10% FBS (Benchmark) and were maintained at 37°C in a humidified 
atmosphere containing 5% CO2.  
 
Spheroid Culture  
24 hours before spheroid plating, U-bottom 96-Well Polystyrene Round Bottom Microwell Plates 
(Fischer Scientific) were coated with Poly(2-hydroxyethyl methacrylate) (polyHEMA) (Sigma).  
Briefly, 2.4g of polyHEMA (Sigma) was dissolved in 20mL of 70% EtOH to make a 10X stock.  A 
1X solution was prepared with 70%EtOH and 30ul per well was added. Plates were left in 
laminar flow hood overnight to ensure EtOH evaporation.  To generate spheroids, cells were 
passaged from monolayer cultures and cells were seeded at 8,000 cells/well in polyHEMA 
coated plates in corresponding normal growth media.  In some experiments, spheroids were 
plated with supplementation of 2% Matrigel™ Membrane Matrix; Growth Factor Reduced 
(Corning) in normal growth media.  For 3D Matrigel spheroids, 100ul of pure Matrigel was 
placed on non-polyHEMA coated U-bottom plates and was placed into 37°C incubator to allow 
for Matrigel solidification.  Subsequently, 8,000 cells/well were plated directly onto Matrigel 
coated plates in normal growth media with the supplementation of 2% Matrigel. To examine 
spheroid viability, 2uM calcein-AM was added to spheroid wells and live spheroids were imaged 
using a fluorescent inverted microscope (Zeiss Axio Vert.A1). 
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Real-time qPCR.  
 
RNA was isolated and purified from cells using High Pure RNA Isolation Kit (Roche Diagnostics) 
following the manufacturer’s instructions. Oligo(dT) primer was used in cDNA synthesis. Briefly, 
200–400 ng of RNA was reverse transcribed in a total volume of 50 μl with a reverse 
transcription reagents kit (Applied Biosystems). To make a standard curve, serial dilutions of 
RNA from one sample were added to the RT reaction. Aliquots (2 μl) of cDNA were added to a 
18 μl reaction mixture containing 10 μlof 2× SYBR® Green PCR Master Mix (BioRad) and 400 
nm primers. The reaction included primer sequences specific to hepcidin, GDF-15 or Cyclophilin 
A depending on the experiments described See Supplemental Table 3-S2 for primer 
sequences.  Absence of DNA contamination was confirmed by performing PCR from cDNA 
without reverse transcriptase.  
Western Blots   
Samples were lysed in 1X RIPA buffer in the presence of protease and phosphatase inhibitors 
(Roche Diagnostics, Basel, Switzerland), were reduced with 10 mM β-mercaptoethanol and 
proteins separated by SDS-PAGE. Western blots were probed with antibodies to phospho-
Smad-1/5/8 (Cell Signaling), hepcidin (Fitzgerald), or β-actin (Abcam). Western blots were 
quantified with Image J.  Hepcidin blots were quantified by normalization to β-actin.   
 
ELISA analysis for secreted GDF-15 
 
GDF-15 was measured in conditioned growth media using a GDF-15 Human ELISA kit from 
R&D systems and following manufacturers’ protocol. Recombinant GDF-15 (R&D systems) was 
used as a positive control. 
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Extracellular Matrix Protein Addition  
 
Before spheroid plating, the addition of 1, 5, 10, or 20 ug/mL of mouse laminin (Corning), mouse 
collagen 1 (MD Biosciences) or Cultrex mouse collagen 4 (R&D systems) was added to cell 
suspension.  Unless otherwise noted, spheroids were harvested after 3 days of ECM treatment.  
 
Statistical analysis 
 
Statistical analyses were performed using Excel and are reported as the mean ± standard 
deviation.  Error bars represent standard deviation. Unless otherwise noted, significant 
differences between control and treatment groups were determined using two-tailed unpaired 
Student’s t tests. 
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Figure 4-1. Addition of Matrigel to breast cancer spheroids limits hepcidin spheroid 
induction.  
(A) Representative images of MCF-7 spheroids without Matrigel (top row; 3D spheroid), with 2% 
Matrigel supplemented in the media (middle row; 2% Matrigel) or embedded into pure Matrigel 
with the addition of 2% Matrigel supplemented in the media (bottom row; 3D Matrigel) at 5X and 
10X magnification.  (B) RT-qPCR of hepcidin (normalized to Cyclophilin A) for MCF-7 cells 
grown in 2D, 3D spheroid, 3D spheroid +2% Matrigel, or 3D pure Matrigel for three days.  
Scale bar=200uM (5X), 100uM (10X) 
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Figure 4-2. Collagen 1 and 4, not laminin, represses hepcidin induction in breast cancer 
spheroids. 
(A) RT-qPCR of hepcidin (normalized to Cyclophilin A) following laminin addition to MCF-7 
spheroids for 3 days. (B) RT-qPCR of hepcidin (normalized to Cyclophilin A) following addition 
of collagen I addition to MCF-7 spheroids for 3 days. (C-E) RT-qPCR of hepcidin (normalized to 
Cyclophilin A) following addition of 10ug/mL collagen I or collagen IV for 3 days in (C) MCF-7 
spheroids, (D)p107Tu spheroids, and (E)p129Tu spheroids.  
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Figure 4-3. Addition of collagen results in decreased GDF-15 secretion and p-SMAD1-5-8 
activity.  
(A) Secreted GDF-15, as detected by ELISA after the addition of 10ug/mL collagen 1, 10ug/mL 
collagen 4 or 1000pg/mL recombinant human GDF-15 (as a control) for 3 days to MCF-7 
spheroids. (B) Western blot analysis of pSmad1-5-8, pro-hepcidin, and β-actin following addition 
of collagen 1 or collagen 4 to MCF-7 spheroids for 3 days. 
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Figure 4-4.  A proposed model for GDF-15 and/or BMP sequestration by collagen in 
breast cancer spheroids.  
In the presence of collagen, GDF-15 and/or BMPs is sequestered and stored in an ECM 
reservoir, preventing its ability to bind and induce a signaling cascade for induction of hepcidin 
in the nucleus.  
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Chapter V:  
Further Characterization of Spheroid Iron Metabolism  
(Unpublished Data) 
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Abstract 
Iron metabolism is altered in breast cancer to favor accumulation of intracellular iron for 
continuous cancer cell proliferation. Hepcidin, a peptide hormone that reduces iron export by 
binding to and degrading the mammalian iron export protein, ferroportin (FPN), is increased in 
breast cancer and is vastly induced by 3D spheroid culture. Due to the nutrient and oxygen 
gradients within spheroids, we hypothesized that hepcidin expression could be altered based on 
modifying these metabolic parameters.  We found that modulation of spheroid metabolic 
parameters directly correlates with hepcidin expression, where hepcidin expression increases 
with more metabolic stress through modulation of spheroid size and nutrients. Furthermore, 
depletion of hepcidin results in decreased spheroid size, suggesting that hepcidin contributes to 
intracellular spheroid iron and subsequent cellular growth. Additionally, other genes that control 
iron metabolism are altered in breast cancer spheroids to favor intracellular iron accumulation. 
Thus targeting increased iron globally, through iron chelation or iron-dependent cell death 
mechanisms, may be the most effective treatment strategy to target iron addicted breast tumors.  
Introduction  
In chapter 3, we observed that hepcidin is induced, simply by culturing cells in 3D, 
suggesting that something intrinsic about spheroid culture is regulating hepcidin.  Overall, we 
found that GDF-15 was majorly responsible for this induction of hepcidin, but it still remains to 
be known how the metabolic properties of spheroids directly influence hepcidin (and GDF-15). It 
is well established that spheroid culture results in nutrient and oxygen gradients, with plentiful 
resources towards the outside of the sphere and decreasing resources towards the spheroid 
core [168].  Thus we hypothesize that as the spheroid increases in size and as nutrients 
become deprived, hepcidin will increase to retain intracellular iron desperately needed as 
nutrients become limited. Additionally, as a result of increased iron, we hypothesize that 
depletion of hepcidin will limit spheroid growth, as iron efflux will be enhanced.  This would 
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coincide with a previous study that found hepcidin depletion in breast cancer xenografts 
reduced tumor growth [28]. 
 In addition to hepcidin induction observed in breast cancer spheroids, other proteins that 
control iron metabolism would be expected to be altered concomitantly with hepcidin, with the 
overall goal of increasing intracellular iron. Breast cancer spheroids would best achieve this goal 
by increasing iron uptake and storage by transferrin receptor (TFR1) and Ferritin (FT) 
respectively, and further reduce iron efflux by basal reduction of surface Ferroportin (FPN). All 
of these proteins are altered in breast cancer, but have never been shown to be further altered 
in spheroid culture of breast cancer cells [6]. As previously mentioned, as spheroids grow, iron 
becomes a limited nutrient and proteins that regulate intracellular iron would need to be altered 
to favor accumulation of iron for growth.   
 Iron is an essential nutrient for tumor cell growth and has long been thought of as an 
attractive target to halt cancer cell proliferation [169].  Since our data from chapter 3 
demonstrates that hepcidin and ferritin are altered in spheroids to promote increased 
intracellular iron, spheroids may be even more susceptible to changes in iron than their own 2D 
counterparts, and better recapitulate iron metabolism present in breast tumors in vivo. Thus, 
utilization of breast cancer spheroids may be an attractive model to assess the effects of iron 
modulators for potential breast cancer therapies.  We hypothesize that breast cancer spheroids 
are be susceptible to cell death by iron depletion. Additionally, as spheroid cells have enhanced 
iron-retaining phenotype, treatment of these spheroids with agents that induce ferroptosis, an 
iron-dependent type of cell death by accumulation of lipid ROS, may unveil a new strategy to 
selectively kill cancer cells with excess iron [170]. 
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Results 
Increased spheroid size and serum starvation increases hepcidin in MCF-7 cells 
Due to the fact that hepcidin is induced in spheroids, most likely as a result the nutrient 
barriers that occur when cells are cultured in 3D, we wondered if altering the size and nutrients 
of spheroid culture would further impact hepcidin expression. To test this, we first cultured MCF-
7 spheroids of different sizes, simply by altering the number of cells plated.  Since most of our 
experiments have utilized 8,000 cells/spheroid at time of plating, we wondered if reducing or 
increasing the number of cells would impact hepcidin expression, as the nutrient gradient would 
be lessened the smaller the spheroid.  As expected, hepcidin expression is increased with 
increasing cell number at time of spheroid plating (Figure 5-1 A and B). Thus, we can conclude 
that by reducing the spheroid size, the fewer amounts of cells are nutrient deprived and 
subsequently, the spheroid has less of a need for hepcidin induction for the goal of iron 
retention.   
 In addition to altering spheroid size, we also wondered if serum starvation would also 
impact hepcidin expression in spheroids, as iron would be severely depleted in serum-deprived 
conditions.  To test this, we cultured MCF-7 spheroids in their normal growth media with 0% 
FBS and examined hepcidin expression.  We found that serum starvation (0% FBS) of 
spheroids further induces hepcidin to a greater extent from monolayer culture (~34 fold) 
compared to induction observed from spheroids cultured in the presence of serum (10% FBS) 
from monolayer culture (~24 fold) (Figure 5-1 C). We next wondered if induction of hepcidin by 
serum starvation was specific for spheroids or if this could also be observed in monolayer 
culture.  Thus, we cultured MCF-7 cells for 3 days in their normal growth media containing 10% 
FBS or normal growth media containing 0% FBS and examined hepcidin expression.  
Consistent with what we observed in spheroids, serum starvation resulted in increased hepcidin 
expression (Figure 5-1D).  This suggests that serum starvation results in increased hepcidin 
expression in monolayers and spheroids, although a direct mechanism for this regulation 
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remains to be elucidated. It is plausible that hepcidin induction present in normal spheroids 
compared to monolayers may be regulated by nutrient deprivation sensing mechanisms, similar 
to mechanisms that regulate increased hepcidin during serum starvation.   
Depletion of spheroid hepcidin levels results in decreased spheroid size 
 Next, we wondered what the physiological consequences of hepcidin induction would be 
in spheroids.  Since hepcidin is induced and we previously showed that ferritin expression was 
increased in spheres compared to monolayer culture (Figure 3-3), we would expect this 
increased iron to be functional and facilitate spheroid growth.  To test this, we depleted hepcidin 
in spheroids utilizing a siRNA knock-down (KD) approach and found that reducing hepcidin 
expression (~90% effective) resulted in a significant reduction in spheroid size after 5 days of 
KD (Figure 5-2). This suggests that hepcidin directly contributes to spheroid size and or/growth, 
most likely though its role in limiting iron export and increasing intracellular iron necessary for 
cell proliferation.  
Other genes that control iron metabolism are altered in breast cancer spheroids 
 In addition to hepcidin, which was mainly the focus of this thesis, we also wondered if 
spheroid culture impacted other proteins that control cellular iron metabolism.  We hypothesized 
that additional iron related genes would be altered in spheroids to favor intracellular iron within 
spheroids. We first examined FPN mRNA expression to see if any changes occurred at the 
mRNA level.  Despite regulation of FPN by IRP post-transcriptionally, and by hepcidin post-
translationally via direct binding, there is some evidence of FPN regulation at the transcriptional 
level, although mechanisms that control this regulation remain partially known [171].  Basal 
levels of FPN transcript are reduced in breast cancer cells compared to non-tumor breast 
epithelial cells [7]. Thus we hypothesized that spheroids, in attempt to retain cellular iron, may 
have reduced FPN transcript as a first line of defense.  We found that compared to monolayer 
MCF-7 cells, MCF-7 spheroids have significantly reduced FPN transcript (Figure 5-3A).  
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 In addition to reducing iron export, we also hypothesized that iron import would be 
increased in spheroids, again favoring accumulation of intracellular iron to overcome nutrient 
deprivation present in spheroids. Thus we examined expression of transferrin receptor (TFR1), 
the cell surface receptor responsible for transferrin-mediated iron uptake, and found a significant 
increase in TFR1 mRNA in MCF-7 spheroids compared to monolayer culture (Figure 5-3B).   
 Lastly, despite our previous findings that ferritin, the iron storage protein that is a 
surrogate marker for intracellular iron, was increased in spheroid culture (Figure 3-3E), we 
wondered if this was also true at the mRNA level. Ferritin was previously found to be 
transcriptionally regulated by oxidative stress [172], thus we hypothesized that as a result of 
spheroid culture ferritin mRNA expression may be increased.  We found a significant increase in 
both Ferritin H and L subunit transcripts in MCF-7 spheroids compared to monolayer culture 
(Figure 5-3C and D).  This may be a direct result of oxidative stress, although future studies 
would elucidate the mechanistic reasoning behind transcriptional elevation of ferritin H and L.  
Taken together, all of these alterations in genes that control iron metabolism suggest 
accumulation of intracellular iron to overcome nutrient limitations present in spheroids in order 
for spheroids to remain viable and proliferate.  
Spheroids are sensitive to iron deprivation and erastin mediated ferroptotic cell death 
 Due to the combination of altered genes that control iron metabolism in spheroids, we 
hypothesized that spheroids would be sensitive to sudden changes in iron. To test this, we first 
treated spheroids with the iron chelator Deferoxamine (DFO) and assessed its effect on 
spheroid viability by calcein and propidium iodide (PI) staining for live and dead cells 
respectively. We noticed that treatment with DFO, either during spheroid plating or treatment 24 
hours after spheroid plating, resulted in a significant increase in cell death and an astounding 
effect of total disruption of spheroid structures (Figure 5-4). Therefore, we concluded that iron is 
essential for maintaining spheroid structure.  
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 Due to the fact that spheroids have altered genes to favor accumulation of intracellular 
iron and are sensitive to chelation of iron, we next wondered if this excess iron retained by 
breast cancer spheroids might enhance their susceptibility to agents that induce ferroptosis.  
Ferroptosis is a newly discovered form of cell death distinguished by its dependence on iron 
[170]. To test this, we treated spheroids with erastin, a small molecule that induces ferroptosis 
or erastin in combination with ferrostatin-1, a specific inhibitor of erastin mediated ferroptotic cell 
death [170].  After staining with calcein and PI, we observed a dramatic increase in cell death 
upon erastin treatment that could be rescued in the presence of ferrostatin-1 (Figure 5-5).  This 
suggests that MCF-7 spheroids are sensitive to erastin mediated ferroptotic cell death.  
 
Discussion  
 In this chapter, we further characterized iron metabolism in spheroids and other potential 
differences in proteins that control iron metabolism between monolayer and spheroid culture.  
Although chapter 3 focused on regulation for hepcidin induction in breast cancer spheroids, we 
wanted to further characterize hepcidin induction and the physiological effects of this increase.  
Thus, we started by examining how alterations to spheroid culture influenced hepcidin 
expression.  We first concluded that hepcidin expression increases with increasing spheroid 
size and that this increase plateaus around 8,000-16,000 cells (Figure 5-1A and B).  This 
corresponds to spheroid literature that larger spheroids (<500uM) have oxygen and nutrient 
gradients present, whereas smaller spheres have more access to those essentials [168]. Thus, 
one could postulate that as the spheroid increases in size, the more that iron becomes limited 
and hepcidin becomes induced to retain intracellular iron already present within those spheroid 
cells.  Furthermore, we also observed that serum starvation has the ability to further induce 
hepcidin in both monolayer and spheroid cultures (Figure 5-1C and D). Without fetal bovine 
serum, which has an abundance of iron, cells must alter the proteins that control iron 
metabolism to ensure that any iron present within the cells does not escape.  Thus, upon serum 
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deprivation, cells up-regulate hepcidin to prevent iron export. Since GDF-15 was found to 
regulate hepcidin induction in breast cancer spheroids, it would be interesting to determine if 
GDF-15 also regulates hepcidin under different iron alterations, such as serum starvation.  If 
there is a direct connection between iron levels and GDF-15, we would want to determine how 
iron directly regulates GDF-15 mechanistically to elicit an effect on hepcidin. A previous 
publication indicated a direct connection between iron and GDF-15, but no mechanistic 
connection was elucidated [173]. 
 In addition to further characterization of hepcidin in spheroids, we also concluded that 
depletion of hepcidin in breast cancer spheroids results in decreased spheroid size (Figure 5-2).  
Although we would need to determine if hepcidin reduction resulted in a decrease in the labile 
iron pool, this suggests that hepcidin plays a role in spheroid growth. Simultaneously with this 
thesis, a group published that depletion of hepcidin in MDA-MB-231 breast cancer cells resulted 
in a significant reduction in tumor growth [28]. Taken together, these data confirm that hepcidin 
would be an attractive molecular target for reducing breast cancer progression.  
 Furthermore, we began to characterize other proteins that control iron metabolism in 
breast cancer spheroids.  Although we only examined proteins at the mRNA level, their patterns 
of expression all favored accumulation of intracellular iron, consistent with our results on 
hepcidin (Figure 5-3).  Transferrin Receptor was increased, indicating that iron import may be 
upregulated in 3D.  Ferritin mRNA was also upregulated in 3D, consistent with increased ferritin 
protein in patient tumor spheroids, shown in Figure 3-3. We also noted that despite tumor cells 
having limited ferroportin expression to start, there seemed to be a decrease in ferroportin 
mRNA in spheroids, again suggesting further reduced iron export in breast cancer spheroids.  
 It is interesting to note that these changes were observed at the mRNA level, where 
most known regulation of TFR1, FT, and FPN occurs post-transcriptionally. Iron regulatory 
proteins (IRP) 1 and 2 are master regulators of cellular iron homeostasis whose main function is 
to increase iron uptake when iron levels are low and decrease iron uptake when iron levels are 
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high [6].  Thus, TFR1, FT and FPN have iron responsive elements (IREs) in the untranslated 
(UTR) of their mRNAs that are bound by IRPs for post-transcriptional regulation. For example, 
when iron is low, IRPs bind to IREs in the 5’ UTR of FT and FPN mRNAs, which inhibits their 
translation and thus inhibits iron storage and efflux. Additionally, IRPs bind to the IRE in the 3’ 
UTR of TFR1 mRNA, resulting in its stabilization and translation of TFR1 to increase iron import.  
Thus, iron directly regulates TFR1, FT and FPN post-transcriptionally, so it is evident that some 
other mechanism exists to alter these iron regulatory genes at the transcriptional level.  This 
regulation warrants investigation to determine the IRP-independent pathways that control these 
genes.  
 Additionally, we would want to observe expression of TFR1 and FPN at the protein level 
in spheroids to determine if the changes present at the mRNA level are consistent at the protein 
level, as we saw in the case of FTH and FTL. If these changes are consistent, this would 
demonstrate that there are global changes in iron metabolism in breast cancer spheroids, all of 
which favor accumulation of intracellular iron and potentially contribute to tumor cell 
progression.   
Global changes in iron, by chelation of iron with DFO in spheroids, demonstrated that 
iron is clearly essential for maintaining spheroid structures (Figure 5-4).  Thus, altering proteins 
that control iron metabolism to promote accumulation of intracellular iron seems to be essential 
for overcoming spheroid nutrient gradients and maintaining tumor growth and progression. 
Interestingly, we may be able to take advantage of this increased iron present in spheroids to kill 
tumor cells by ferroptosis (Figure 5-5). It would be interesting to see if tumor spheroids are more 
sensitive to ferroptotic cell death compared to non-tumor spheroids, as their levels of iron would 
be much greater and render them more susceptible to ferroptotic inducing agents. Ferroptosis 
may prove to be an advantageous way to selectively kill tumor cells that have selfishly 
increased their iron levels for continuous cell growth and tumor progression. 
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Materials and Methods  
 
Cell Line Culture 
MCF-7 cells were obtained from the Wake Forest University Comprehensive Cancer Center 
Tissue Culture Core facility and verified by ATCC cell authentication testing service. MCF-7 
cells were cultured in Dulbecco’s minimal essential medium (DMEM)–F12 (Gibco) 
supplemented with 10% FBS (Benchmark) and were maintained at 37°C in a humidified 
atmosphere containing 5% CO2.  
 
Spheroid Culture  
24 hours before spheroid plating, U-bottom 96-Well Polystyrene Round Bottom Microwell Plates 
(Fischer Scientific) were coated with Poly(2-hydroxyethyl methacrylate) (polyHEMA) (Sigma).  
Briefly, 2.4g of polyHEMA (Sigma) was dissolved in 20mL of 70% EtOH to make a 10X stock.  A 
1X solution was prepared with 70%EtOH and 30ul per well was added. Plates were left in 
laminar flow hood overnight to ensure EtOH evaporation.  To generate spheroids, cells were 
passaged from monolayer cultures and cells were seeded at 8,000 cells/well in polyHEMA 
coated plates in corresponding normal growth media unless otherwise noted. In some 
experiments, 2000, 4000 and 16,000 cells were also used to generate spheroids and some 
spheroids were cultured without serum as specified.  Live spheroids were imaged using a 
fluorescent inverted microscope (Zeiss Axio Vert.A1). 
 
Real-time qPCR.  
RNA was isolated and purified from cells using High Pure RNA Isolation Kit (Roche Diagnostics) 
following the manufacturer’s instructions. Oligo(dT) primer was used in cDNA synthesis. Briefly, 
200–400 ng of RNA was reverse transcribed in a total volume of 50 μl with a reverse 
transcription reagents kit (Applied Biosystems). To make a standard curve, serial dilutions of 
RNA from one sample were added to the RT reaction. Aliquots (2 μl) of cDNA were added to a 
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18 μl reaction mixture containing 10 μlof 2× SYBR® Green PCR Master Mix (BioRad) and 400 
nm primers. The reaction included primer sequences specific to hepcidin, ferroportin, transferrin 
receptor, Ferritin H, Ferritin L and Cyclophilin A depending on the experiments described. See 
Supplemental Table 3-S2 for primer sequences. Absence of DNA contamination was confirmed 
by performing PCR from cDNA without reverse transcriptase.  
DFO and Erastin Treatment  
8000 MCF-7 cells were seeded in 96-well ultra-low attachment plates for spheroid formation and 
treated with deferoxamine mesylate (Sigma), erastin (Selleckchem, Houston, TX, USA) or 
ferrostatin-1 (Selleckchem) either during spheroid plating or 24 hours after spheroid formation. 
Puromycin was used as a positive control of cell death. To examine spheroid viability, 2μM 
calcein-AM (Life Technologies) and 4μM propidium iodide (PI) (Life Technologies) was added to 
spheroid wells and live spheroids were imaged using a fluorescent inverted microscope (Zeiss 
Axio Vert.A1). 
 
siRNA Knock-down  
All reagents were obtained from GE Dharmacon (Lafayette, CO, USA). ON-TARGETplus 
human SMARTpools were used for siHAMP(cat#: L-014014-00-0010) and siNTC (cat#: D-
001810-10-05) were used for knockdown experiments. Transfections were performed in MCF-7 
cells according to the manufacturer’s recommendations using Dharmafect #1 (T-2001) 
transfection reagent and normal growth media without serum. Knock-down was performed in 
monolayer culture for 24 hours before trypansization of cells and subsequent spheroid plating. 
Effect on spheroid size was determined from imaging 3 spheroids for each condition after 6 
days of KD (5 days as spheroids). Hep KD efficiency was confirmed at this time-point by RT-
qPCR.  
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Statistical Analysis 
Statistical analyses were performed using Excel and are reported as the mean ± standard 
deviation.  Error bars represent standard deviation. Unless otherwise noted, significant 
differences between control and treatment groups were determined using two-tailed unpaired 
Student’s t tests. 
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Figure 5-1.Hepcidin expression is further increased with increasing spheroid size or 
serum starvation. 
(A) Representative images of spheroids cultured at initial seeding densities of 2000, 4000, 8000 
o 16,000 MCF-7 cells respectively after 7 days in culture. (B). RT-qPCR of hepcidin mRNA 
(normalized to Cyclophilin A) of spheroids with varying seeding densities after 7 days in culture. 
(C) RT-qPCR of hepcidin mRNA (normalized to Cyclophilin A) of MCF-7 cells grown as 
monolayers or spheroids in normal growth medium (containing 10% FBS) or spheroids grown in 
medium containing no serum (0%FBS) after 7 days in culture. (D) RT-qPCR of hepcidin mRNA 
(normalized to β-actin) in MCF-7 cells grown in medium containing no serum or 10% serum for 
3 days.  
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Figure 5-2.  Hepcidin knock-down results in decreased spheroid size.  
(A) Spheroid area as measured from images acquired after knock-down (KD) of hepcidin (Hep) 
or scramble (Scrbl) non-targeting control following 6 days of KD or untreated spheroids (Unt). 
(B) RT-qPCR of of UNT, NTC and Hep siRNAs after 6 days in MCF-7 spheroids to display 
knock-down efficiency.  
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  A          B 
Figure 5-3. Other iron related genes favor accumulation of intracellular iron in MCF-7 
spheroids.  
RT-qPCR of (A) Ferroportin (B) Transferrin Receptor (C) Ferritin L and (D) Ferritin H mRNA (all 
normalized to Cyclophilin A) for MCF-7 monolayer and spheroids after 3 days in culture.  
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Figure 5-4. Iron chelation results in disruption of spheroid structures.  
Calcein (2uM) and Propidium Iodide (PI) (4uM) staining (top row) and corresponding phase 
contrast images (bottom row) of MCF-7 spheroids after 5 days of no treatment (UNT) or addition 
of 100uM DFO treatment (added during spheroid plating or added 24 hours after spheroid 
plating). Puromycin was used as a positive control for spheroid cell death.  
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Figure 5-5. Spheroids are sensitive to erastin via ferroptosis mediated cell death.   
Representative images (RI) from untreated MCF-7 spheroids (UNT), spheroids treat with 50uM 
erastin, or spheroids treated with 50uM erastin in addition to 2uM ferrostatin for rescue.  
Treatments were completed 24 hours after spheroids were plated. Spheroids were harvested 48 
hours following treatment. 
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Conclusions & Future Directions 
 Hepcidin was originally discovered in the liver for control of systemic iron homeostasis 
[37].  Our lab was among the first to reveal that hepcidin is conserved in peripheral tissues, 
including the breast epithelium, for control of cellular iron homeostasis [7].  Although hepcidin 
regulation has been extensively studied in the liver, the mechanisms that regulate hepcidin in 
breast cancer cells remained unknown, until now. Ultimately, in this thesis we found that 
hepcidin is regulated by a complex network of protein molecules and spatial cues, consisting of 
changes at the cellular, dimensional and micronevironmental levels during breast cancer 
progression. Revealing these mechanisms that regulate hepcidin in breast cancer now provides 
novel targets for the ultimate goal of decreasing cancer cell iron and preventing the detrimental 
effects that arise from its excess.   Based on the chapters in this thesis we arrive at 3 main 
conclusions and provide directions for which this research can continue.  
A. Positive regulation of hepcidin in breast cancer involves BMPs, GDF-15 and IL-6  
(Chapters 2 and 3) 
Through investigation of the pathways that control positive regulation of hepcidin in 
breast cancer, we uncovered a dynamic network of positive regulators, including BMPs, IL-6 
and GDF-15. We utilized various in vitro culture systems to uncover these molecular players in 
regulation of hepcidin. First, utilizing traditional monolayer culture, we found that the main 
positive regulators of hepcidin in the liver were conserved in the breast (Chapter 2).  
Specifically, these included BMP4, BMP6, BMP7 and IL-6.  Interestingly, all of the breast cancer 
cell lines we examined displayed varied preferences and response by these ligands in 
regulation of hepcidin. Specifically, different breast cancer cells had varied basal expression of 
BMPs/IL-6 as well as varied response to perturbation of these ligands.  However, at least one of 
these ligands was conserved for regulation of hepcidin in monolayer culture (Figure 2-2 through 
2-7 and Figure 3-1).  Additionally, induction of hepcidin by all of these ligands was shown to be 
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functional, as treatment of T47-D breast cancer cells with BMPs or IL-6 resulted in decreased 
FPN membrane staining (Figure 2-9). Furthermore, treatment of normal human mammary 
epithelial (HME) cells with IL-6 resulted in hepcidin induction (Figure 2-8).  This suggests that IL-
6 mediated regulation of hepcidin is conserved in normal breast cells.  This would infer that if an 
extracellular source of IL-6 was present, hepcidin could be increased in the non-malignant 
breast for local degradation of FPN, leading to accumulation of intracellular iron and potential 
increased proliferation and iron mediated DNA damaging events. It is possible that increased 
hepcidin in non-tumorigenic cells could be an early transformation event.  In the next 
conclusion, we will discuss the potential exogenous sources of IL-6 from the microenvironment.  
Taken together, our data demonstrates that BMPs and IL-6 are conserved regulators of 
hepcidin in breast tissue and these ligands are elevated in breast cancer cells for increased 
basal hepcidin expression.  Thus, these ligands and their downstream signaling pathways would 
be attractive molecular targets for reduction of hepcidin and ultimately intracellular iron in breast 
cancer cells.  
In addition to traditional monolayer culture, we also utilized three-dimensional culture 
systems of both established cancer cell lines as well as primary patient breast cells to elucidate 
hepcidin regulation in breast cancer (Chapter 3).  3D culture was performed to better 
recapitulate breast tumor architecture and metabolism, in order to capture the full spectrum of 
hepcidin regulation.  Serendipitously, we found that hepcidin was drastically induced by 
spheroid culture of breast cancer lines and primary cells compared to monolayer culture, 
suggesting novel regulation of hepcidin through spatial cues (Figure 3-2, Figure 3-3 and 
Supplementary Figure 2-S2). Ultimately, we found only a modest contribution of BMPs/IL-6 in 
this induction between dimensions (Figure 3-4), but instead revealed GDF-15 as the main 
dimensional regulator of hepcidin in breast cancer spheroids (Figure 3-6).  Although we still 
have yet to understand what regulates GDF-15 in breast cancer spheroids, we found that GDF-
15 directly regulates hepcidin induction through a conserved BMP signaling pathway involving 
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activation of downstream signal mediators, including SMAD1-5-8 and SMAD4 (Figure 3-6).  It 
would be interesting to extend these studies to in vivo systems, to determine if depletion of 
GDF-15 in breast tumor xenografts in mice results in decreased breast tumor SMAD signaling, 
hepcidin expression, tumor iron and an overall reduction of tumor growth. Furthermore, previous 
studies have found that GDF-15 up-regulates IL-6 to promote tumorigenesis in prostate cancer 
cells[174].  It would be interesting to determine if such crosstalk exists in breast tumor spheroids 
between GDF-15 and IL-6 and/or BMPs, for further (or perhaps synergistic) positive control of 
hepcidin in breast cancer.   
In addition to the regulators identified in this study, it is possible that additional regulators 
remain unknown for tight regulation of hepcidin in breast cancer.  Although GDF-15 played a big 
role in hepcidin induction in spheroid culture of breast cancer cells, there were several other 
genes that were up-regulated in our microarray analysis completed in chapter 3. Although many 
of these genes are most likely correlated with hepcidin induction in spheroids, it is possible that 
some of these up-regulated genes play a role, either indirect or direct, in regulation of hepcidin 
induction in breast cancer spheroids. Previous studies have linked hypoxia with regulation of 
hepcidin [64, 66-68]. It is known that spheroids have increased hypoxia, due to oxygen 
gradients [168].  Although changes in HIF occur at the protein level and were not detected by 
the microarray, other hypoxia target genes, such as VEGF, were increased in MCF-7 spheroids 
compared to monolayer.  This supports the idea of a hypoxic environment in these spheroids 
and that this hypoxia could contribute to hepcidin induction in breast cancer spheroids. This 
potential regulatory mechanism could be explored through modulation of HIF proteins.  
In addition to hypoxia, another potential relationship between spheroid literature and 
hepcidin could be relevant.  It is known that spheroid culture of breast cancer cells enhances a 
stem-like cell population, where cells in the spheroid core take on a less proliferative and more 
quiescent-like state.  In the breast, these cells are characterized molecularly by low CD24 
expression and high CD44 expression [175].  We found that CD44 was ~8-9 fold increased in 
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breast cancer spheroids compared to monolayer as expected from the literature.  Thus, a 
correlation exists between increased hepcidin and stem like cells in spheroids. Interestingly, our 
lab and others have previously found that tumor initiating cells or cancer stem cells have an 
enhanced iron seeking phenotype[29, 176, 177]. Furthermore, a recent study suggested that 
GDF-15 plays a role in the maintenance of breast cancer stem-like cells [135]. Thus, it would be 
interesting to determine if a mechanistic connection exists between GDF-15, hepcidin and stem 
cells.  It is possible that hepcidin is induced by GDF-15 in spheroids as a result of the increased 
iron demands of stem like cells.  
Overall, positive regulation of hepcidin seems to be majorly controlled by BMPs, GDF-15 
and IL-6 in breast tumors. Although additional regulators may exist and would have to be further 
characterized, the identification of these factors in regulation of hepcidin in breast cancer cells 
provides molecular targets for reduction of hepcidin in breast tumors. As these regulators are all 
secreted proteins, targeted antibodies would be a great strategy for inhibiting the activation of 
pathways that contribute to in increased hepcidin expression and breast tumor growth.  
B. Regulation of hepcidin by the microenvironment  
(Chapters 3 and 4) 
In addition to regulation of hepcidin by the tumor epithelial cells themselves, we also 
wondered if the tumor microenvironment may play a role in hepcidin regulation, as evidence 
supports a significant role of the microenvironment in breast cancer progression [178]. These 
experiments included investigation into the role of stromal cells, specifically tumor associated 
fibroblasts (TAFs) (Chapter 3), as well as the extracellular matrix (ECM) (Chapter 4) in 
regulation of hepcidin in breast cancer.  
We first examined the potential regulation of hepcidin by stromal cells within the tumor 
microenvironment.  We began by isolating and propagating TAFs from breast cancer patients, 
and subsequently performed co-culture experiments with various tumor epithelial cells.   
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Following co-culture, we examined the potential multi-cellular regulation of hepcidin in breast 
cancer, as TAFs have been well characterized to contribute to breast cancer progression 
through direct signaling to TECs [179].  Interestingly, we found that TAFs further contribute to 
hepcidin expression and that this was mediated by paracrine regulation involving secretion of IL-
6 by TAFs (Figure 3-8). 
Since these experiments were conducted using TAFs from only one patient, it would be 
interesting to determine if other TAFs have a similar effect on hepcidin, mediated by IL-6. 
Furthermore, we would also like to investigate the effect of non-tumor breast fibroblasts on 
hepcidin regulation in TECs.  It would also be worthwhile to conduct in vivo co-culture 
experiments and analyze TAF effect on hepcidin, tumor iron and tumor growth over time. Since 
MCF-7 and primary patient cells are slow growing as tumor xenografts, they would be a good 
model cell line to conduct such co-culture in vivo experiments.  Furthermore, although GDF-15 
was not secreted by this specific patients’ TAFs used for this thesis, other studies have 
identified TAF derived GDF-15 in prostate cancer, in which this TAF produced GDF-15 
contributed to tumorigenesis at both a local and systemic level [139]. Thus, we would like to 
extend these studies through use of additional patient TAFs.  Ultimately, these studies support a 
pro-tumorigenic role of TAFs in breast cancer, which is in part due to paracrine production of IL-
6 for increased production of hepcidin in breast TECs.  
It would also be interesting to isolate additional stromal cells, such as adipocytes and 
macrophages from the tumor microenvironment and asses their contribution to hepcidin 
regulation and iron metabolism in breast TECs.  Interestingly, studies have found hepcidin 
production from adipose tissue, which could potentially degrade FPN on TECs for increased 
iron retention [180]. Furthermore, tumor associated macrophages, which have increased iron 
stores, could act iron donors, where their iron stores could directly transfer iron to TECs for 
subsequent tumor growth [181]. The contribution by these additional stromal cells to hepcidin 
and iron metabolism deserves investigation in the context of breast tumors. 
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 In addition to stromal cells, this thesis identified a novel dynamic role of the extracellular 
matrix (ECM) in regulation of hepcidin in breast cancer spheroids. We first concluded that 
Matrigel repressed the induction of hepcidin in breast cancer spheroids, and subsequently 
identified collagen as the main ECM protein responsible for this reduction of hepcidin at early 
time points (Figure 4-1 and Figure 4-2).  Ultimately, one of the potential mechanisms by which 
collagen represses hepcidin was found to be through sequestration of GDF-15, as its presence 
in the media and downstream signaling through pSMAD1-5-8 was reduced in the presence of 
collagen (Figure 4-3).  Although the exact dynamics and specifics of this effect have yet to be 
characterized, we hypothesize that collagen acts as a storage depot for GDF-15.  When tumor 
cells require increased iron, GDF-15 would be released from collagen for activation of the 
downstream signaling pathway for induction of hepcidin.  Thus, in the future we hope to further 
characterize this interaction between collagen and GDF-15 and how their association tightly 
regulates hepcidin expression over time in breast cancer spheroids.  In addition, we would like 
to examine additional contribution of the ECM, such as fibronectin or vimentin on hepcidin 
expression and other players of iron metabolism, as these ECM proteins have also been 
attributed to progression of breast cancer [145]. In this thesis, we have only just begun to 
understand the complex relationship between the extracellular matrix and iron metabolism in 
breast cancer and hope to continue to elucidate this relationship in the future.  
 Overall, the data in this thesis was the first to provide scientific evidence between the 
tumor microenvironment in regulation of hepcidin. The role of the microenvironment is emerging 
in progression of tumors, especially of the breast.  Thus, when developing new treatment 
strategies, components of the microenvironment, such as stromal cells and ECM must be 
considered, especially for targeting iron metabolism.  
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C. Global iron metabolism alterations in breast cancer spheroids 
(Chapters 3 and 5) 
 Due to the fact that hepcidin was induced simply by three-dimesnsional culture, we 
hypothesized that this effect may be due to nutrient and oxygen gradients present within 
spheroids.  Thus, we postulated that hepcidin expression could be altered based on modifying 
these metabolic parameters.  Through modulation of spheroid nutrients and size, we found a 
direct correlation with hepcidin expression (Figure 5-1).  Hepcidin expression increased with 
depleted iron via serum starvation and larger nutrient gradients due to size limitations. 
Furthermore, depletion of hepcidin results in decreased spheroid size (Figure 5-2), suggesting 
that hepcidin contributes to intracellular spheroid iron and subsequent cellular growth, 
consistent with hepcidin depletion in breast tumor xenografts [28]. 
In addition to our investigation into hepcidin expression and the regulatory pathways that 
control its expression in breast cancer, we also examined other changes in iron metabolism and 
the effects of iron perturbation in breast cancer spheroids. Since there are many proteins that 
control cellular iron metabolism, we postulated that in addition to hepcidin, other iron related 
proteins would be altered to favor enhanced iron retention in breast cancer spheroids.  Indeed, 
we found alteration of other genes that control iron metabolism.  Specifically, we found 
increased TFR1 mRNA in MCF-7 spheroids (Figure 5-3), which would promote spheroid iron 
uptake. Additionally, we found increased Ferritin H and L mRNA and protein (Figure 3-3 and 
Figure 5-3), suggesting that iron stores are enhanced in spheroids.  Lastly, we found decreased 
FPN mRNA in spheroids (Figure 5-3), implying that FPN is basally reduced transcriptionally, 
before hepcidin mediated FPN degradation occurs at the post-translational level.  Although 
these changes between monolayer and spheroid culture would need to be confirmed at the 
protein level for FPN and TFR1, all of these modifications are consistent with a pattern of 
increased iron retention in breast cancer spheroids.  Overall, this suggests that breast cancer 
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spheroids alter several iron metabolism genes to attain enhanced spheroid iron for survival and 
growth.   
Due to these dimensional changes in iron metabolism genes to promote enhanced 
spheroid iron acquisition, we postulated that global perturbation of the iron would be detrimental 
to spheroid viability.  Thus, when spheroid iron was chelated, spheroid cell death was observed 
and spheroid formation was completely disrupted (Figure 5-4).  This supports the hypothesis of 
spheroid demand for iron for growth and further displays a role of iron for tumor architectural 
maintenance.  Overall, this supports therapeutic intervention by targeting genes that control iron 
metabolism for the goal of reducing iron within breast tumors.   
As this thesis has alluded to, future directions of this project hope to target regulatory 
mechanisms that control hepcidin.  However, due to the dynamic regulation of hepcidin 
involving TECs and the microenvironment, in addition to alteration of several other genes that 
control iron metabolism, future treatment strategies to deplete tumors of iron may have to take 
on a more global approach.  It is possible that selective targeting of hepcidin in breast tumors 
may only work temporarily, before other iron metabolism proteins become altered to 
compensate and increase intracellular iron levels for continued growth.  Thus, more general 
strategies of targeting enhanced spheroid iron may have to be explored.   
One potential iron targeting therapy in cancer would be through ferroptosis, a newly 
discovered form of non-apoptotic cell death that is dependent on iron [170].  Mechanistically, 
cell death by ferroptosis is caused by iron-mediated accumulation of lipid ROS [182]. Induction 
of ferroptosis by small molecules, such as erastin, reduced ovarian tumor mass in vivo and was 
also found to selectively kill ovarian cancer tumor initiating cells compared to non-cancer stem 
cells, as labile iron is higher in the tumor initiating cells compared to non-cancer stem cells[29].  
In this thesis, we successfully induced ferroptotic cell death in breast cancer spheroids (Figure 
5-5), suggesting that enhanced iron presence in spheroids can be targeted by ferroptosis 
inducing agents. We would also want to extend our investigation of ferroptosis to non-tumor 
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breast spheroids, as one would hypothesize that lower iron present in non-tumor spheroids 
would render them less susceptible to death by ferroptosis.  Together, this data demonstrates 
that that breast cancer spheroids would be a good model system to further explore this 
treatment strategy and suggests that enhanced iron seeking phenotype present in breast 
tumors may be targeted via ferroptosis. 
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